5th THERANOSTICS World Congress 2019

MARCH 1 - 3, 2019
THE SHILLA JEJU HOTEL, JEJU, KOREA

www.theranostics2019.org

Organized by
Korean Association for Nuclear Medicine Promotion

Supported by
WELCOME MESSAGE FROM CO-CHAIRPERSONS

Dear Colleagues and Friends,

Theranostics is THE way to make nuclear medicine REVIVE. Theranostics World Congress in 2019 (TWC2019) is the fifth occasion following the first in Bad Berka of Germany (Richard Baum), India, USA, and Australia, now in Korea.

In March 1-3 2019 in Jeju of Korea, the world’s leading experts will present their future prospects of expanding theranostics to other diseases than the currently well-established NET and CRPC treatments. Uniquely here, the next-generation leaders from Asia and developing countries are going to be invited by KAST (Korean Academy of Science and Technology) with the help of EU (TEIN: Trans-Eurasia Information Network) and KOICA (Korea International Cooperation Agency) and will join and discuss their start-up endeavor in theranostics in each country/ institution.

Expanding vision beyond the current status quo in theranostics and nuclear medicine and geographic expansion of this breakthrough are the two main goals of this TWC2019. Your participation will accomplish the long-overdue aim.

See you all in fantastic Jeju.

All the best,

Dong Soo Lee, M.D., Ph.D
Co-Chairperson of TWC 2019
President, World Federation of Nuclear Medicine and Biology (WFNMB)

Jae Min Jeong, Ph.D
Co-Chairperson of TWC 2019
President, Society of Radiopharmaceutical Sciences (SRS)
ORGANIZING COMMITTEE

<table>
<thead>
<tr>
<th>Co-Chairpersons</th>
<th>Dong Soo Lee</th>
<th>Korea</th>
<th>Nuclear Medicine, College of Medicine, Seoul National University</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jae Min Jeong</td>
<td>Korea</td>
<td>Nuclear Medicine, College of Medicine, Seoul National University</td>
</tr>
<tr>
<td>Honorary Advisors</td>
<td>Myung Chul Lee</td>
<td>Korea</td>
<td>The Korean Academy of Science and Technology</td>
</tr>
<tr>
<td></td>
<td>Richard Baum</td>
<td>Germany</td>
<td>THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Central Clinic Bad Berka</td>
</tr>
<tr>
<td>Secretary-General</td>
<td>Gi Jeong Cheon</td>
<td>Korea</td>
<td>Nuclear Medicine, College of Medicine, Seoul National University</td>
</tr>
<tr>
<td></td>
<td>Jung-Joon Min</td>
<td>Korea</td>
<td>Nuclear Medicine, Chonnam National University Medical School</td>
</tr>
<tr>
<td></td>
<td>Byeong-Cheol Ahn</td>
<td>Korea</td>
<td>Nuclear Medicine, Kyungpook National University School of Medicine</td>
</tr>
<tr>
<td>Organizing Committee</td>
<td>Jae Sung Lee</td>
<td>Korea</td>
<td>Nuclear Medicine, College of Medicine, Seoul National University</td>
</tr>
<tr>
<td></td>
<td>So Won Oh</td>
<td>Korea</td>
<td>Nuclear Medicine, College of Medicine, Seoul National University</td>
</tr>
<tr>
<td></td>
<td>Yun-Sang Lee</td>
<td>Korea</td>
<td>Nuclear Medicine, College of Medicine, Seoul National University</td>
</tr>
</tbody>
</table>
SCIENTIFIC COMMITTEE

Patricia Bernal Trujillo  
Colombia  
Fundacion Santa Fe de Bogota, University Hospital

Savvas Frangos  
Cyprus  
Bank of Cyprus Oncology Centre

Dae Yoon Chi  
Korea  
Chemistry, Sogang University

Keon Wook Kang  
Korea  
Nuclear Medicine, College of Medicine, Seoul National University

Seigo Kinuya  
Japan  
Nuclear Medicine, Kanazawa University

Yuji Kuge  
Japan  
Central Institute of Isotope Science, Hokkaido University

Makoto Hosono  
Japan  
Radiology, Institute of Advanced Clinical Medicine, Kindai University

Noboru Oriuchi  
Japan  
Fukushima Global Medical Science Center, Fukushima Medical University

Feng Wang  
China  
Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University

Hong Zhang  
China  
Nuclear Medicine and Molecular Imaging, Zhejiang University School of Medicine, Shanxi Medical University

Xiaoli Lan  
China  
Nuclear Medicine and PET Center, Wuhan Union Hospital

Zhaozhu Zhu  
China  
Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College

Ting Kun Au Yong  
Hong Kong  
Nuclear Medicine, Queen Elizabeth Hospital

Greta Seng Peng Mok  
Macau  
Health Science, University of Macau

Lingeswaran Kasilingam  
Malaysia  
Nuclear Medicine Imaging, Beacon Hospital

David Ng  
Singapore  
Nuclear Medicine and Molecular Imaging, Singapore General Hospital

Wen-Sheng Huang  
Taiwan  
Nuclear Medicine, Taipei Veterans General Hospital

Pham Cam Phuong  
Vietnam  
The Nuclear Medicine and Oncology Center, Bach Mai Hospital

Hendra Budiawan  
Indonesia  
Nuclear Medicine, Hasan Sadikin Hospital, Bandung

Shamim Monimaz Ferdousi Begum  
Bangladesh  
PET-CT, National Institute of Nuclear Medicine & Allied Sciences

Baljinder Singh  
India  
Nuclear Medicine & PET, PGIMER

Partha S. Choudhury  
India  
Nuclear Medicine, Rajiv Gandhi Cancer Institute & Research Centre

Rakesh Kumar  
India  
Nuclear Medicine, All India Institute of Medical Sciences (AIIMS)

Enkhtuya Byambajav  
Mongolia  
Nuclear Medicine, National Central Hospital Ulaanbaatar

Kyin Myint  
Myanmar  
Myanmar Nuclear Medicine Society

Patricia Bautista  
Philippines  
Nuclear Medicine, St. Luke’s Medical Center

Humayun Bashir  
Pakistan  
Nuclear Medicine, Shaukat Khanum Memorial Cancer Hospital & Research Centre

M. Fani Bozkurt  
Turkey  
Nuclear Medicine, Hacettepe University

Akram Al-Ibraheem  
Jordan  
Nuclear Medicine, King Hussein Cancer Center

Michael Hofman  
Australia  
Molecular Imaging and Nuclear Medicine Therapeutics, Peter MacCallum Cancer Centre
SCIENTIFIC COMMITTEE

Mike Sathekge  
South Africa  
Nuclear Medicine, University of Pretoria

Richard Baum  
Germany  
THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Central Clinic Bad Berka

Frank Rösch  
Germany  
Institute for Nuclear Chemistry, Johannes Gutenberg-University Mainz

Hans-Jürgen Wester  
Germany  
Pharmaceutical Radiochemistry, Technical University of Munich

Markus Essler  
Germany  
Nuclear Medicine, University Hospital Bonn

Michael Kreissl  
Germany  
Radiology and Nuclear Medicine, University Hospital Magdeburg

Kambiz Rahbar  
Germany  
Nuclear Medicine, University Hospital Münster

Wolfgang Weber  
Germany  
Nuclear Medicine, Technical University of Munich

Matthias Eiber  
Germany  
Nuclear Medicine, Technical University of Munich

Klaus Kopka  
Germany  
Radiopharmaceutical Chemistry, German Cancer Research Center

Andreas Kjaer  
Denmark  
Medical & Molecular Imaging, University of Copenhagen

Marion de Jong  
The Netherlands  
Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam

Mark Konijnengen  
The Netherlands  
Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam

Stefano Fanti  
Italy  
Experimental, Diagnostic and Specialty Medicine, University of Bologna

Carlos Buchpiguel  
Brazil  
Radiology and Oncology, São Paulo University School of Medicine

Juliano Julio Cerci  
Brazil  
PET/CT center, Quanta - Diagnosis and Therapy

Richard Wahl  
USA  
Mallinckrodt Institute of Radiology, Washington University

Andrei Iagaru  
USA  
Nuclear Medicine and Molecular Imaging, Stanford University

Martin Pomper  
USA  
Nuclear Medicine and Molecular Imaging, Johns Hopkins University

Josh Mailman  
USA  
NorCal CarciNet Community

Cathy S. Cutler  
USA  
Medical Isotope Research Production & Development Group (MIRP), Brookhaven National Laboratory

Henry VanBrocklin  
USA  
Radiology and Biomedical Imaging, University of California San Francisco

Michael K. Schultz  
USA  
Nuclear Medicine, Radiology, University of Iowa

Hongdi Li  
USA  
United Imaging Healthcare America, Inc.

Steve Yoon-Ho Cho  
USA  
Radiology, University of Wisconsin - Madison

Weibo Cai  
USA  
Radiology, University of Wisconsin - Madison

Anna Wu  
USA  
Molecular Imaging and Therapy, Beckman Research Institute of the City of Hope

Michael R. Zalutsky  
USA  
Radiology, Duke University School of Medicine
# PROGRAM AT A GLANCE

<table>
<thead>
<tr>
<th>DATE</th>
<th>FRIDAY (MARCH 1, 2019)</th>
<th>SATURDAY (MARCH 2, 2019)</th>
<th>SUNDAY (MARCH 3, 2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:00</td>
<td>Opening Ceremony</td>
<td>Keynote 3</td>
<td>Scientific Session 5-3</td>
</tr>
<tr>
<td>09:00-10:00</td>
<td>Coffee Break and Exhibition</td>
<td>Scientific Session 3-2</td>
<td>&lt;Next Generation Theranostics (from Innovators' Point of View)&gt;</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td>Keynote 1</td>
<td>Reports 2</td>
<td>Coffee Break and Exhibition</td>
</tr>
<tr>
<td>11:00-12:00</td>
<td>Scientific Session 1</td>
<td>Reports 1</td>
<td>Read with the Experts</td>
</tr>
<tr>
<td></td>
<td>&lt;Current Status of Theranostics&gt;</td>
<td>&lt;Global Practical Progress&gt;</td>
<td>&lt;Selected Poster Presentation&gt;</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Lunch</td>
<td>Scientific Session 4</td>
<td>Share the Experiences</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt;Next Generation Theranostics (from Physicists' Point of View)&gt;</td>
<td>&lt;Open Discussion&gt;</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>Poster and Exhibition</td>
<td>TEIN Luncheon Seminar</td>
<td>Keynote 6</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>Keynote 2</td>
<td>Poster and Exhibition</td>
<td>Closing Ceremony</td>
</tr>
<tr>
<td>15:00-16:00</td>
<td>Scientific Session 2</td>
<td>Keynote 5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;Theranostics of Prostate Cancer&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00-17:00</td>
<td>Reports 1</td>
<td>Scientific Session 5-1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;Current Status of Theranostics in Asia&gt;</td>
<td>&lt;Next Generation Theranostics (from Convergents' Point of View)&gt;</td>
<td></td>
</tr>
<tr>
<td>17:00-18:00</td>
<td>Scientific Session 3-1</td>
<td>Scientific Session 5-2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;Next Generation Theranostics (from Chemists' Point of View)&gt; - Novel Targets and Probes&gt;</td>
<td>&lt;Next Generation Theranostics (from Physicians' Point of View)&gt;</td>
<td></td>
</tr>
<tr>
<td>18:00-19:00</td>
<td>Coffee Break and Exhibition</td>
<td>Reports 3</td>
<td></td>
</tr>
<tr>
<td>19:00-20:00</td>
<td>Welcome Reception</td>
<td>Speaker/Chair/Panelists Dinner</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lotus Hall (3F)</td>
<td>(Invited Only)</td>
<td></td>
</tr>
</tbody>
</table>

Legend:
- **Opening Ceremony**
- **Keynote**
- **Scientific Session**
- **Reports**
- **Poster and Exhibition**
- **Coffee Break and Exhibition**
- **TEIN Luncheon Seminar**
- **Closing Ceremony**

**FRIDAY (MARCH 1, 2019)**
- 08:00: Opening Ceremony
- 12:00: Lunch

**SATURDAY (MARCH 2, 2019)**
- 09:00: Keynote 3
- 11:00: Reports 2
- 1:00: Scientific Session 4
- 3:00: TEIN Luncheon Seminar
- 5:00: Keynote 5
- 7:00: Reports 3

**SUNDAY (MARCH 3, 2019)**
- 09:00: Scientific Session 5-3
- 11:00: Coffee Break and Exhibition
- 13:00: Read with the Experts
- 15:00: Share the Experiences
- 17:00: Keynote 6
- 19:00: Closing Ceremony
VENUE MAP

6F

Registration Desk
Ora
- Secretariat
Halla Hall
Weolla
- Preview Room
Mara
- VIP Room
Coffee Break

3F

Lotus Hall
- Welcome Reception (March 1)
- Participants Lounge
Lily / Lobby of Lotus Hall
- Poster Session Area
Lobby of Lotus Hall

It looks like are 3 floors in between, but in reality it is the next floor; participants can easily use the stairs.
CONGRESS INFORMATION

PREVIEW ROOM
All invited (oral) speakers are requested to visit the preview room no later than 1 hour before their session. They will be assisted by our staff members who will help upload the presentation files to the server before the session.

<table>
<thead>
<tr>
<th>Date / Time</th>
<th>Place</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 1 (Fri.) - 2 (Sat.) / 08:00-18:00</td>
<td>Weolla (6F)</td>
</tr>
<tr>
<td>March 3 (Sun.) / 08:00-12:00</td>
<td>Weolla (6F)</td>
</tr>
</tbody>
</table>

REGISTRATION
All participants are required to check in at the registration desk to pick up their name badge. Badges must be worn during all scientific sessions and social programs. Lost name badges will not be reissued.

<table>
<thead>
<tr>
<th>Date / Time</th>
<th>Place</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 1 (Fri.) - 2 (Sat.) / 08:00-18:00</td>
<td>Lobby of Halla Hall (6F)</td>
</tr>
<tr>
<td>March 3 (Sun.) / 08:00-13:00</td>
<td>Lobby of Halla Hall (6F)</td>
</tr>
</tbody>
</table>

* On-site Registration Fees

<table>
<thead>
<tr>
<th>Category</th>
<th>Registration Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Registration (Professor)</td>
<td>USD 1,200</td>
</tr>
<tr>
<td>Student Registration &lt;#&gt;</td>
<td>USD 350</td>
</tr>
<tr>
<td>Additional Accompanying Person &lt;@&gt;</td>
<td>USD 500</td>
</tr>
</tbody>
</table>

※ "Student" Category <#> includes Residents, Interns, Fellows, Students and Researchers.
※ <#> Participants who want to register as "Student" Category are requested to submit certificates verifying their status of Residents, Interns, Fellows, Students or Researchers to the registration desk.
※ <@> "Additional Accompanying Person" Category: Only 1 person is available.

LUNCH
Lunch will be provided to all participants at luncheon symposiums during the congress as followings. Please show your name badge to the hotel staff.

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Type</th>
<th>Place</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 1</td>
<td>12:00-13:00</td>
<td>Lunch Box</td>
<td>Halla Hall (6F)</td>
</tr>
<tr>
<td>March 2</td>
<td>12:30-13:30</td>
<td>Lunch Box</td>
<td>Halla Hall (6F)</td>
</tr>
</tbody>
</table>

FREE WI-FI
The organizing committee is pleased to offer Free Wi-Fi to all participants during the congress. Free Wi-Fi is available on the 6th floor and the 3rd floor.

CERTIFICATE OF ATTENDANCE & RECEIPT
Certificates of attendance, presentation and receipt will be issued after the congress through email by request.
CONGRESS INFORMATION

SOCIAL PROGRAM

Opening Ceremony
All registered participants are invited to the Opening Ceremony. Please join and congratulate the official opening of TWC 2019.

<table>
<thead>
<tr>
<th>Date / Time</th>
<th>Place</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 1 (Fri.) / 08:30-09:30</td>
<td>Halla Hall (6F)</td>
</tr>
</tbody>
</table>

Welcome Reception
An official welcome reception will be held to celebrate TWC 2019. Do not miss this special chance to meet participants from around the world.

<table>
<thead>
<tr>
<th>Date / Time</th>
<th>Place</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 1 (Fri.) / 18:30-</td>
<td>Lotus Hall (3F)</td>
<td>Free (Name badges are required.)</td>
</tr>
</tbody>
</table>

Coffee / Tea
Coffee and tea will be provided in the lobby of 6F during morning and afternoon breaks.

Closing Remarks
The closing ceremony will be held to celebrate the success of programs and to cherish the memories from TWC 2019.

<table>
<thead>
<tr>
<th>Date / Time</th>
<th>Place</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 3 (Sat.) / 12:10-13:00</td>
<td>Halla Hall (6F)</td>
</tr>
</tbody>
</table>

LOST AND FOUND
Lost items should be returned to the registration desk (6F). Should you lose anything, please report to the registration desk (6F).

PARTICIPANTS LOUNGE
The Participants Lounge is for all participants to unwind and rest during the congress.

<table>
<thead>
<tr>
<th>Date / Time</th>
<th>Place</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 1 (Fri.) - 2 (Sat.) / 08:00-18:00</td>
<td>Lotus Hall (3F)</td>
</tr>
<tr>
<td>March 3 (Sun.) / 08:00-13:00</td>
<td>Lotus Hall (3F)</td>
</tr>
</tbody>
</table>

USEFUL WEBSITES & PHONE NUMBERS

Useful Websites
· Korea Tourism Organization (http://english.visitkorea.or.kr)
· Visit Jeju (https://www.visitjeju.net/en)
· Jeju International Airport (https://www.airport.co.kr/jejueng/main.do)

Phone Numbers
· Emergencies for Fire / Rescue & Hospital Services 119
· Police 112
· Visit Jeju +82-64-740-6000 (From Korean Phone: 064-740-6000)
  (In addition to Korean, Visit Jeju offers service in three other languages English, Chinese and Japanese by phone from 09:00-18:00.)
· The Shilla Jeju Hotel +82-64-735-5114 (From Korean Phone: 064-735-5114)
SPONSORS & EXHIBITORS

The TWC 2019 Organizing Committee greatly appreciates the generous support of our sponsors and exhibitors.

GOLD

SIEMENS Healthineers

GE Healthcare

SILVER

CellBion

Eckert & Ziegler

itm

INNOVATION

EXHIBITION

BRIGHTONIX IMAGING

Eckert & Ziegler

itm

POLATOM

TEMA SINERGIE

ABX

BRUKER

CheMatech

THERAGNOSTICS

REELIT

mim

SUMITOMO (NISHIO INDUSTRIES, LTD.

ABX

KDepRI

FUTURECHEM

ABX

CONGRESS BADGE

CONGRESS BAG
EXHIBITION

OVERVIEW

Date / Time
March 1 (Fri.) – 2 (Sat.) / 08:00-18:00
March 3 (Sun.) / 08:00-13:00

Location
Lobby, 6F & 3F

EXHIBITION LIST

Booth No. Company

1-2 SIEMENS Healthineers
5 CellBion
7 ITM Isotopen Technologien München AG
9 Boo Kyung S-M Co., Ltd.
14 IBA SA
16 POLATOM
18 YAKJIN E-MEDICS CO., LTD.
20 Bruker
22 Theragnostics
24 IRE Elit
26 Nuclear Medicine and Molecular Imaging
28 IDB Holland B.V, an AAA company
30 ABX advanced biochemical compounds GmbH
32 KDePrl(KIRAMS)
34 Scintomics Molecular, Applied Theranostics Technologies GmbH (“att”)
36 ICRT 2019

Booth No. Company

3-4 GE Healthcare
6 NEW KOREA INDUSTRIAL CO., LTD.
8 Brightonix Imaging Inc.
10 Eckert & Ziegler
15 CHAYON Laboratories. Inc.
17 Tema Sinergie S.p.A.
19 iPHASE technologies
21 CHEMATECH
23 Trasis
25 MIM Software
27 Center of Molecular Research Ltd.
29 Sumitomo Heavy Industries, Ltd.
31 Quantum Healthcare Korea Co., Ltd
33 FutureChem Co., Ltd.
35 JSC Isotope
DAILY PROGRAM

MARCH 1
MARCH 2
MARCH 3
DAILY PROGRAM

MARCH 1 (FRI.)

08:30-09:30 OPENING CEREMONY
Gi Jeong Cheon (Seoul National University, Korea)

Opening, KAST International Symposium
Congratulatory Remarks
Myung Chul Lee (The Korean Academy of Science and Technology (KAST), Korea)

Appreciation Plaque for Past Organizers
Dong Soo Lee (Seoul National University, Korea)
Jae Min Jeong (Seoul National University, Korea)

Opening Remarks
Jae Min Jeong (Seoul National University, Korea)
Dong Soo Lee (Seoul National University, Korea)

09:30-10:00 COFFEE BREAK AND EXHIBITION

10:00-10:30 KEYNOTE 1
Chair Dong Soo Lee (Seoul National University, Korea)

Uncovering Novel Biomarkers for Next Generation Theranostics
Sunghoon Kim (Seoul National University, Korea)

10:30-12:00 SCIENTIFIC SESSION 1: CURRENT STATUS OF THERANOSTICS
Chairs Kyung Han Lee (The Korean Society of Nuclear Medicine (KSNM), Korea)
Horacio Amaral (PositronMed, Chile)

Clinical Trials Supporting FDA/EMA Approval of Lutathera
Tessa Brabander (Erasmus Medical Center, The Netherlands)

Clinical Experiences with PSMA-1007: Current Status
Kambiz Rahbar (University Hospital Münster, Germany)

Clinical Experiences of $^{177}$Lu PSMA Combined or for Other Cancers
Markus Essler (University Hospital Bonn, Germany)

Future of Theranostics in Germany
Wolfgang Weber (Technical University of Munich, Germany)

Future Perspectives of Theranostics in USA
Richard Wahl (Washington University, USA)

12:00-13:00 LUNCH
**DAILY PROGRAM**

**MARCH 1 (FRI.)**

13:00-14:00  **POSTER AND EXHIBITION**  
Lobby of lotus hall(3f)

14:00-14:30  **KEYNOTE 2**  
Chair: Richard Wahl (Washington University, USA)  
Practical Applications and Future Prospects of Radiotheranostics  
Michael Hofman (Peter MacCallum Cancer Centre, Australia)

14:30-15:30  **SCIENTIFIC SESSION 2: THERANOSTICS OF PROSTATE CANCER**  
Chairs: Gi Jeong Cheon (Seoul National University, Korea)  
Hee-Seung Bom (Chonnam National University, Korea)  
Unmet Clinical Needs in Advanced Prostate Cancer  
Cheol Kwak (Seoul National University, Korea)  
Targeting Non-cullin Neddylation to Combat Neoplastic and Metabolic Diseases  
Yang-Sook Chun (Seoul National University, Korea)  
Simplest Glu-Urea-Lys (EUK) for PSMA  
Yun-Sang Lee (Seoul National University, Korea)  
Theranostic Agents for Targeting PSMA: Development of $^{18}$F and Alpha Emitters  
Dae Yoon Chi (Sogang University, Korea)

15:30-16:00  **REPORTS 1: CURRENT STATUS OF THERANOSTICS IN ASIA**  
Chair: Keon Wook Kang (Seoul National University, Korea)  
Theranostics in Korea  
Keon Wook Kang (Seoul National University, Korea)  
Theranostics in Japan  
Seigo Kinuya (Kanazawa University, Japan)  
Theranostics in China  
Feng Wang (Nanjing Medical University, China)

16:00-16:30  **COFFEE BREAK AND EXHIBITION**

16:30-18:00  **SCIENTIFIC SESSION 3-1: NEXT GENERATION THERANOSTICS (FROM CHEMISTS’ POINT OF VIEW) - NOVEL TARGETS AND PROBES**  
Chairs: Frank Rösch (Johannes Gutenberg-University Mainz, Germany)  
Henry VanBrocklin (The University of California, San Francisco, USA)  
Instant Kit-type Labelling Chemistry for $^{68}$Ga, $^{44}$Sc, $^{177}$Lu.  
Frank Rösch (Johannes Gutenberg-University Mainz, Germany)
Image Guided Therapy: Development of Oncologic and Non-oncologic Agents
Henry VanBrocklin (The University of California, San Francisco, USA)

Potential Use of Hypoxia and Thymidine Phosphorylase Imaging Probes for Theranostics
Yuji Kuge (Hokkaido University, Japan)

Imaging of the Third Gasotransmitter
Jae Min Jeong (Seoul National University, Korea)
DAILY PROGRAM

MARCH 2 (SAT.)

08:00-08:30

KEYNOTE 3
Chair: Dae Yoon Chi (Sogang University, Korea)

Radiohybrids: A Groundbreaking New Theranostics Tracer Concept
Hans-Jürgen Wester (Technical University of Munich, Germany)

08:30-09:30

SCIENTIFIC SESSION 3-2: NEXT GENERATION THERANOSTICS (FROM CHEMISTS’ POINT OF VIEW) - ALPHA EMITTERS

Chairs: Baljinder Singh (PGIMER, India)
        Cathy S. Cutler (Brookhaven National Laboratory, USA)

Precision Treatment: Production of Alpha Emitters for Targeted Therapies to Kill Cancer Cells
Cathy S. Cutler (Brookhaven National Laboratory, USA)

\[^{203}\text{Pb}^{212}\text{Pb}\] Peptide Receptor Targeted Theranostics for Cancer
Michael K. Schultz (University of Iowa, USA)

The Heidelberg Series of Glu-ureido based PSMA Tracers: Adaption of Chemical Structure to Clinical Indication
Klaus Kopka (German Cancer Research Center, Germany)

09:30-10:30

REPORTS 2: GLOBAL PRACTICAL PROGRESS

Chairs: Patricia Bernal Trujillo (Fundacion Santa Fe de Bogota, University Hospital, Colombia)
        Mike Sathekge (University of Pretoria, South Africa)

Implementation of Novel Theranostics in Africa
Mike Sathekge (University of Pretoria, South Africa)

Struggles of Theranostics in Latin America
Patricia Bernal Trujillo (Fundacion Santa Fe de Bogota, University Hospital, Colombia)

Theranostics Efforts between Europe and Asia
M. Fani Bozkurt (Hacettepe University, Turkey)

Optimization of Novel Radionuclide Therapies in India
Partha Choudhury (Rajiv Gandhi Cancer Institute & Research Centre, India)

PSMA PET in Initial Management of Prostate Cancer; Experience from the Arab World
Akram Al-Ibraheem (King Hussein Cancer Center, Jordan)

10:30-11:00

COFFEE BREAK AND EXHIBITION

11:00-11:30

KEYNOTE 4
Chair: Richard Baum (Central Clinic Bad Berka, Germany)

Intelligence-based vs Evidence-based: How AI will Shape the Future of Theranostics to Achieve True Personalized Medicine
Anthony Chang (BAMF Health, USA)
MARCH 2 (SAT.)

11:30-12:30
Scientific Session 4: Next Generation Theranostics (From Physicists’ Point of View)

Chairs
Mark Konijnenberg (Erasmus Medical Center, The Netherlands)
Jae Sung Lee (Seoul National University, Korea)

Prospective Dosimetry Options for Alpha-emitter Targeted Therapy
Mark Konijnenberg (Erasmus Medical Center, The Netherlands)

Voxel-based Dosimetry of $^{177}$Lu-IONPs-folate using SPECT/CT Imaging of Mice
Arun Gupta (BPKIHS, Nepal)

New Approaches to Fast Voxel-based Dosimetry
Jae Sung Lee (Seoul National University, Korea)

ICRP Perspectives for Individualized Radionuclide Therapy
Makoto Hosono (Kindai University, Japan)

12:30-14:00
Tein Luncheon Seminar

Chairs
Dong Soo Lee (Seoul National University, Korea)
Teik-Hin Tan (Sunway Medical Centre, Malaysia) via Tein Video Conferencing

On-Site Speakers
Lingeswaran Kasilingam (Beacon Hospital, Malaysia)
Hendra Budiawan (Hasan Sadikin Hospital, Bandung, Indonesia)
Pham Cam Phuong (Bach Mai Hospital, Vietnam)
Shamim Momtaz Ferdousi Begum (National Institute of Nuclear Medicine & Allied Sciences, Bangladesh)
Noboru Oriuchi (Fukushima Medical University, Japan)
Ting Kun Au Yong (Queen Elizabeth Hospital, Hong Kong)
David Ng (Singapore General Hospital, Singapore)
Hong Zhang (Shanxi Medical University, China)
Humayun Bashir (Shaukat Khanum Memorial Cancer Hospital & Research Centre, Pakistan)
Patricia Bautista (St. Luke’s Medical Center, Philippines)

Participants who Connect via Tein Video Conferencing from their Home Country
Sadia Sultana (Bangladesh), Karisma Perdani (Indonesia), Wong Tect Huat (Malaysia),
Jefferson Pagsisihan, Apichaya Ciamon, Tawatchai Chaiwatanarat (Thailand),
Nguyen Thuan Loi (Vietnam)

14:00-14:30
Poster and Exhibition
Lotus hall lobby (3f)

14:30-15:00
Keynote 5

Chair
Hans-Jürgen Wester (Technical University of Munich, Germany)

Personalized Cancer Therapy: From Innovation to Implementation using Theranostics and Precision Oncology
Richard Baum (Central Clinic Bad Berka, Germany)
DAILY PROGRAM _ MARCH 2 (SAT.)

15:00-16:00 SCIENTIFIC SESSION 5-1: NEXT GENERATION THERANOSTICS (FROM CONVERGENTS’ POINT OF VIEW)

Chairs
Jung-Joon Min (Chonnam National University, Korea)
Anna Wu (Beckman Research Institute of the City of Hope, USA)

Antibody Theranostics
Anna Wu (Beckman Research Institute of the City of Hope, USA)

In Vitro to in Vivo Companion Diagnostics
Young Kee Shin (Seoul National University, Korea)

Bacteria-based Radio-theranostics
Jung-Joon Min (Chonnam National University, Korea)

Gastrin-Releasing Peptide Receptors for Theranostics in Prostate Cancer
Andrei Iagaru (Stanford University, USA)

16:00-16:30 COFFEE BREAK AND EXHIBITION

16:30-17:50 SCIENTIFIC SESSION 5-2: NEXT GENERATION THERANOSTICS (FROM PHYSICIANS’ POINT OF VIEW)

Chairs
Michael Kreissl (University Hospital Magdeburg, Germany)
Steve Yoon-Ho Cho (University of Wisconsin - Madison, USA)

Theranostics in Combination with Local Therapies
Michael Kreissl (University Hospital Magdeburg, Germany)

PSMA Targeting Alpha Therapies
Wolfgang Weber (Technical University of Munich, Germany)

Immune Cell-based Theranostics
Il Minn (Johns Hopkins University, USA)

Imaging Criteria for Assessing Response to Theranostics – Challenges and Opportunities
Steve Yoon-Ho Cho (University of Wisconsin - Madison, USA)

17:50-18:20 REPORTS 3: STANDPOINTS OF PATIENT ADVOCATES

Chairs
Keon Wook Kang (Seoul National University, Korea)
Josh Mailman (NorCal CarciNet Community, USA)

USA Experiences
Josh Mailman (NorCal CarciNet Community, USA)

Korean Experiences
Song-hoon Ham (Korea)

Japanese Experiences
Yoshiyuki Majima (NPO PanCAN, Japan)
DAILY PROGRAM MARCH 3 (SUN.)

08:00-09:20 SCIENTIFIC SESSION 5-3: NEXT GENERATION THERANOSTICS (FROM INNOVATORS' POINT OF VIEW)
Chairs
Dong Soo Lee (Seoul National University, Korea)
Beat Loeffler (CLINAM - European Foundation for Clinical Nanomedicine, Switzerland)

Nanomedicine: 11 Years of European Efforts of the European Foundation for Clinical Nanomedicine
Beat Loeffler (CLINAM - European Foundation for Clinical Nanomedicine, Switzerland)

Introduction to Radionanomedicine
Dong Soo Lee (Seoul National University, Korea)

Radiolabeled Nanomaterials
Weibo Cai (University of Wisconsin - Madison, USA)

Ceria-based Nanoparticle Therapy against ROS-mediated Injury
Seung-Hoon Lee (Seoul National University, Korea)

Theranostics of Exosomes on Alzheimer's disease
Ren-Shyan Liu (Taipei Veterans General Hospital, Taiwan)

09:20-09:40 COFFEE BREAK AND EXHIBITION

09:40-10:40 READ WITH THE EXPERTS: SELECTED POSTER PRESENTATION
Chairs
Richard Baum (Central Clinic Bad Berka, Germany)
Byeong-Cheol Ahn (Kyungpook National University, Korea)

In the Assessment of Biodistribution and Metabolism for α-Methylation on 18F-Labeled Tryptophan Derivative
Ho Young Kim (Seoul National University, Korea)

Enhancing SSTR2-Targeted Alpha-Particle Therapy for Neuroendocrine Tumors with Everolimus and Histone Deacetylase Inhibitors
Dongyoul Lee (University of Iowa, USA)

Targeted Alpha-Particle Therapeutics - Adaptation of Clinical Routinely Produced Ac-225-Labeled Radiopharmaceuticals
Dirk Müller (Central Clinic Bad Berka, Germany)

First-In-Human Study of a Novel Somatostatin Receptor Antagonist 68Ga-NODAGA-LM3 for Molecular Imaging of Paraganglioma Patients
Jingjing Zhang (Central Clinic Bad Berka, Germany)

Treatment of Predominantly Lymph Node Metastatic Prostate Cancer with 177Lu-PSMA Radioligand Therapy
Danielle Meyrick (GenesisCare, Australia)

Chemokine Receptor CXCXR4-targeted PET/CT with 64Ga-pentixafor Shows Superiority to 18F-FDG in Evaluation of Multiple Myeloma
Yaping Luo (Peking Union Medical College Hospital, China)
DAILY PROGRAM  MARCH 3 (SUN.)

10:40-11:40  SHARE THE EXPERIENCES - OPEN DISCUSSION: HOW TO IMPLEMENT NOVEL THERANOSTICS OVERCOMING DIFFICULTIES OF STARTING INSTITUTIONS

Chairs  Gi Jeong Cheon (Seoul National University, Korea)
        Mike Sathekge (University of Pretoria, South Africa)

Panels from the Starting Institutions
        Wen-Sheng Huang (Taipei Veterans General Hospital, Taiwan)
        Lingeswaran Kasilingam (Beacon Hospital, Malaysia)
        Hendra Budiawan (Hasan Sadikin Hospital, Bandung, Indonesia)
        Pham Cam Phuong (Bach Mai Hospital, Vietnam)
        Shamim Momtaz Ferdousi Begum (National Institute of Nuclear Medicine & Allied Sciences, Bangladesh)
        Patricia Bautista (St. Luke's Medical Center, Philippines)
        Humayun Bashir (Shaukat Khanum Memorial Cancer Hospital & Research Centre, Pakistan)

11:40-12:10  KEYNOTE 6

Chair  Edmund Kim (MD Anderson Cancer Center, USA)

Brain Theranostics
        Dong Soo Lee (Seoul National University, Korea)

12:10-13:00  CLOSING REMARKS

Gi Jeong Cheon (Seoul National University, Korea)

Hand-over Ceremony to the Next Congress Chairpersons
FROM
        Dong Soo Lee (Seoul National University, Korea)
        Jae Min Jeong (Seoul National University, Korea)

TO
        Horacio Amaral (PositronMed, Chile)
        Vasko Kramer (PositronPharma, Chile)
INVITED SPEAKERS
KEYNOTE SPEAKERS

Sunghoon Kim
Seoul National University, Korea
March 1 (Fri.) / 10:00-10:30

Uncovering Novel Biomarkers for Next Generation Theranostics
Sunghoon Kim received bachelor’s degree at Seoul National University College of Pharmacy, master’s degree at Korea Advanced Institute of Science and Technology Department of Biological Sciences, Korea and PhD degree at Division of Biology and Medicine, Brown University, USA. He then worked as post-doctoral fellow at MIT. He is currently a professor at College of Pharmacy and also at Graduate School of Convergence Technology of Seoul National University. He received several prestigious awards provided by various scientific communities as well as by Korean government such as the Korea scientist award (2003), the scientist of the year (2006), the Best Scientist Award(2012) and Ho-Am Prize(2015). Since 2010, he is leading “Medicinal Bioconvergence Research Center” that is one of the biggest top-down research projects launched by the ministry of science, ICT and Future Planning (MSIP). In this project, he is paving a rapid and efficient target identification and validation system through integrated biology with convergence technologies and is linking this system to facilitate novel drug discovery.

Michael Hofman
Peter MacCallum Cancer Centre, Australia
March 1 (Fri.) / 14:00-14:30

Practical Applications and Future Prospects of Radiotheranostics
Professor Michael Hofman is a nuclear medicine physician at the Centre for Molecular Imaging, Cancer Imaging at the Peter MacCallum Cancer Centre in Melbourne, Australia’s only public hospital dedicated to cancer treatment, research and education. He previously completed a fellowship at Guy’s & St Thomas’ in London, and was a consultant at Monash Health and MIA. He has a broad interest in positron emission tomography (PET), molecular imaging applications in oncology and theranostics (radionuclide therapy). He has a vision of improving patient outcomes by using molecular imaging to non-invasively characterise disease enabling improved selection of the most appropriate therapy for an individual patient and better assessment of therapeutic response. He has particular interest in novel F-18 and Ga-68 PET radiotracers, and theranostic applications including prostate and neuroendocrine tumours. As a scientific committee member of Australasian Radiopharmaceutical Trials Network (ARTnet) he supports the development of high-quality clinical trials. He is currently the principal investigator of the proPSMA multi-centre randomised trial of PSMA PET for staging prostate cancer, and the TheraP multi-centre randomised trial of Lu-177 PSMA therapy. He has authored over 100 peer-reviewed articles and several book chapters. He is currently an Associate Editor for several journals including Cancer Imaging, Leukaemia Lymphoma, and the Journal of Medical Imaging and Radiation Oncology (JMIRO), and is the Vice-Chairperson of the Oncology Scientific Committee for the Society of Nuclear Medicine and Molecular Imaging.
KEYNOTE SPEAKERS

Hans-Jürgen Wester
Technical University of Munich, Germany
March 2 (Sat.) / 08:00-08:30

Radiohybrids: A Groundbreaking New Theranostics Tracer Concept

* Scientific Career History
- 1992 Diploma (Chemistry/Radiochemistry), University of Cologne and Research Center Juelich
- 1996 Ph.D., Radiopharmaceutical Chem, Research Center Juelich
- 1995-2004 Scientific Assistant and Research Associate, Department of Nuclear Medicine, Technische Universität München Academic Appointments
- 2004-2010 Professor (C3) of Radiopharmaceutical Chemistry, TUM, Faculty of Medicine, Nuclear Medicine Co-appointment at the Faculty of Chemistry
- 2010- Full Professor (W3), Pharmaceutical Radiochemistry, TUM, 1st Full Appointment at the Faculty of Chemistry, 2nd Full Appointment at the Faculty of Medicine Co-Speaker of the Collaborative Research Center (SFB 824) of the German Research Foundation, Member of the Board of the German Society for Nuclear Medicine (2009-2012)

Anthony Chang
BAMF Health, USA
March 2 (Sat.) / 11:00-11:30

Intelligence-based vs Evidence-based: How AI will Shape the Future of Theranostics to Achieve True Personalized Medicine

Dr. Anthony Chang is a scientist, educator, and healthcare pioneer with a mission to revolutionize the treatment of Cancer, Alzheimer’s, Parkinson’s, and Cardiovascular diseases. In 2018, Dr. Chang founded Bamf Health, with a vision to save lives by coupling Artificial Intelligence (AI) with noninvasive molecular imaging and molecular targeted radiation therapy (Theranostics) for precise early diagnosis and effective treatment.

Dr. Chang has been on the forefront of discovering and developing high-tech, breakthrough diagnostic methods and treatments for diseases with a primary focus on cancer. From his work with some of the leading academic medical centers, Dr. Chang has developed cutting-edge systems for facilitating the clinical translation including comprehensive facility management, automated image fusion and atlas-based segmentation to achieve high throughput real-time image analysis.

Dr. Chang holds a BS in Medical Imaging and Radiological Sciences from Chang Gung University, Taiwan. He received postgraduate training in Biomedical Engineering at Yale University’s NMR Center and Vanderbilt University Institute of Imaging Science and earned his PhD in Medical Physics from University of Texas Health Science Center at San Antonio, specializing in diagnostic imaging physics. He was the founding director of the preclinical Imaging center and Laboratory of Translational Imaging of Van Andel Research Institute. In 2016, Dr. Chang received the Outstanding Alumni Award from Chang Gung University, and is one of the honorees of 2016 Grand Rapids Business Journal 40 under 40 class. In 2017, he received The Henry Dunant Global Impact Award from the American Red Cross which was inspired by his work on developing and promoting molecular imaging technology. He was also appointed by Michigan Governor Rick Snyder as a commissioner to the Michigan Asian Pacific American Affairs Commission in early 2017.
KEYNOTE SPEAKERS

Richard Baum
Central Clinic Bad Berka, Germany
March 2 (Sat.) / 14:30-15:00

Personalized Cancer Therapy: From Innovation to Implementation using Theranostics and Precision Oncology
1996-present Professor of Nuclear Medicine, University of Frankfurt/Main
1997-present Chairman and Clinical Director, THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka, Germany
1989 Election, President of IRIST, Mallinckrodt Award (German Society of Nuclear Medicine)
1996 Sharabai Memorial Oration Award, Society of Nuclear Medicine India
2003 Docente Especial de Professor Invitado del Inst. Sup. de Ciencias Med. Habana/Cuba
2010 F.Y. Khoo Lectureship and Medal, Academy of Medicine & Singapore Radiological Society, Singapore
2011 Agasthiai Award by the Indian Society of Nuclear Medicine
2013 Re-election, President of the International Research Group in Immunoscintigraphy and Immunotherapy (IRIST)
2013 President, World Association of Radionuclide and Molecular Therapy (WARMTH)
2015 Appointment as Board Member of the Therapy Center of Excellence of the SNMMI
2016 Appointment as Member of the Publication Committee of the SNMMI
2017 Appointment by ESMO as Faculty Member for the CUP and Endocrine Tumors
2017 Henry Wagner, Jr. Lectureship at the Annual Meeting in Denver

Dong Soo Lee
Seoul National University, Korea
March 3 (Sun.) / 11:40-12:10

Brain Theranostics
As a nuclear medicine physician, I am interested in brain studies and radionanomedicine. In the early days, I was involved in nuclear cardiology, brain mapping and molecular imaging sequentially in my carrier since I started nuclear medicine in 1990 as faculty in Seoul National University and Seoul National University Hospital, Korea. Finally now I study brain connectivity using PET/MRI which are based on topological interpretation of the group PET and individual resting-state MRI. Recently, moving from molecular imaging to nanomedicine and theranostics, I just published a book by Springer, ‘Radionanomedicine; combined nuclear and nanomedicine’. I believe that radionanomedicine is the way how nanomedicines (nanodrugs or nanomaterials) enter into the clinical discipline. I am currently taking the role of President of World Federation of Nuclear Medicine and Biology (2019-2020) and also joining International Society for Nanomedicine working as Vice-President.
INVITED SPEAKERS

Tessa Brabander
Erasmus Medical Center, The Netherlands

March 1 (Fri.)

Clinical Trials Supporting FDA/EMA Approval of Lutathera

Dr. Tessa Brabander is a nuclear medicine physician from the Erasmus MC, Rotterdam, The Netherlands. She received her PhD on imaging and therapy of neuroendocrine tumors with radiolabeled somatostatin analogs under the supervision of Prof.dr. Dik J Kwekkeboom.

Currently, she is the section head of nuclear medicine at the department of Radiology & Nuclear medicine. Her main research interests are imaging and therapy of neuroendocrine tumors, and other radionuclide therapy.

Kambiz Rahbar
University Hospital Münster, Germany

March 1 (Fri.)

Clinical Experiences with PSMA-1007: Current Status

Kambiz Rahbar is senior attending physician at the department of Nuclear Medicine at the University Hospital Muenster, Germany. During the past years he had major contributions in the field of prostate cancer theranostics, especially radionuclide therapy of metastasized castration prostate cancer patients using prostate specific membrane antigen (PSMA) ligands. His landmark publications and his personal contributions are crucial factors in the development and planning of the running Phase III "VISION" trial using Lu-177-PSMA-617.

Kambiz Rahbar has been awarded by different medical societies, among them the George von Hevesy-Award of the German Society of Nuclear Medicine for his work on PSMA targeted imaging and best clinical publication and best paper award of the Journal of Nuclear Medicine, warded at the SNMMI annual meeting 2018.

Markus Essler
University Hospital Bonn, Germany

March 1 (Fri.)

Clinical Experiences of $^{177}$Lu PSMA Combined or for Other Cancers

*Scientific degrees / Board certification*
2010 Habilitation in Nuclear Medicine, TUM (Advisor: Prof. Dr. M. Schwaiger)
06/2007 Board Certification Nuclear Medicine
2004 Habilitation in Clinical Pathophysiology, LMU Munich (Advisor: Prof. Dr. P.C. Weber)
1996 Doctoral Thesis (magna cum laude), LMU Munich (Advisor: Prof. Dr. P.C. Weber)

*Professional Development (Post University Degree)*
Since 2010 Senior Physician, Department of Nuclear Medicine, Klinikum rechts der Isar, Munich
2007-2010 Clinical Resident, Department of Nuclear Medicine, Klinikum rechts der Isar, Munich
2000-2002 Postdoctoral Fellow, The Burnham Institute, Cancer Research Center, LA Jolla, USA
1999-2000 Clinical Resident, Medical Department, LMU, Munich
1996-1999 Postdoctoral Research Assistant, Institute for Prevention of Cardiovascular Diseases, LMU, Munich
INVITED SPEAKERS

Wolfgang Weber
Technical University of Munich, Germany

March 1 (Fri.)

Future of Theranostics in Germany
Wolfgang Weber, MD is Professor and Chair of the Department of Nuclear Medicine at the Technical University of Munich in Germany (TUM). Dr. Weber is a graduate of the TUM Medical School. He was trained in Nuclear Medicine at TUM and joined the faculty of the Department of Nuclear Medicine at TUM in 2001. From 2004-2007, he was Associate Professor at the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA). In 2007 he was appointed Professor and Chair of the Department of Nuclear Medicine at the University of Freiburg in Germany. In 2013 he returned to the USA and became Chief of Nuclear Medicine at the Memorial Sloan Kettering Cancer Center as well as Professor of Radiology at the Weill Cornell Medical College. He held both positions until the end of 2017. Dr. Weber’s research is focused on molecular imaging of cancer for planning and monitoring of therapeutic interventions. He is also interested in targeted radionuclide therapy of cancer and theranostics. Dr. Weber has published more than 250 papers in leading scientific journals including the Journal of Clinical Oncology, PNAS as well journals of the Nature series. He has served on the editorial board of several scientific journals such as the Journal of Nuclear Medicine, European Journal of Nuclear Medicine and Molecular Imaging, Clinical Cancer Research and Journal of Clinical Oncology.

Richard Wahl
Washington University, USA

March 1 (Fri.)

Future Perspectives of Theranostics in USA
Dr. Wahl has had a long standing interest in quantitative imaging of cancer and its response to therapy. His focus has been on PET and SPECT methods, but also on fused imaging methods in which multiparametric signatures can be derived from PET and MRI—the topic of the U-01 project he directs. He authored the PERCIST criteria and is very interested in applying such methods of high precision imaging to assessing sequential quantitative cancer studies before and after treatment with use of imaging methods to individually adapt therapies to specific patients early after treatment begins. He is also active in developing and testing new radiopharmaceutical therapies of cancer and in integrating them into cancer treatment regimens.
INVITED SPEAKERS

**Cheol Kwak**  
Seoul National University, Korea  
March 1 (Fri.)

**Unmet Clinical Needs in Advanced Prostate Cancer**
Dr. Cheol Kwak, Professor of the Department of Urology, is Chief of Urologic Cancer and Prostate Cancer Center in Seoul National University Cancer Hospital, and also Chief of Robot Surgery Center in Seoul National University Hospital. He graduated from Seoul National University College of Medicine in 1991. After completing his postgraduate training as the specialty of urological oncology in 2002 at Seoul National University, Dr. Kwak pursued research fellowship at the Seoul National University Hospital and the University of California, Irvine in the U.S. He has been working for Seoul National University Hospital since 2003, as a faculty, specializing in urological oncology and robot-assisted laparoscopic surgery. Dr. Kwak has co-authored more than 170 papers in peer-reviewed journals and contributed to several book chapters. He has also been the Principal Investigator of a number of clinical trials on urological oncology areas. And currently, he is an active member and director of several professional organizations, including the American Urological Association, Korean Urologic Association, Korean Urologic Oncology Society and Korean Prostate Society, etc.

**Yang-Sook Chun**  
Seoul National University, Korea  
March 1 (Fri.)

**Targeting Non-cullin Neddylation to Combat Neoplastic and Metabolic Diseases**
Dr. Yang-Sook Chun now is a professor at Seoul National University College of Medicine. Dr. Chun received a doctoral degree from Seoul National University in 1991. Dr. Chun was a visiting scientist at Department of Carcinogenesis, National Cancer Institute in Tokyo by joining to the Nakasone Program from 1992 to 1994. Next, she moved to Harvard Medical School in Boston and spent 2 years (1996 to 1998) as a visiting scholar; a year at Brigham & Woman’s Hospital and second year at Mass General Hospital. Then she has served for the Seoul National University. Dr. Chun received the Good Scientist Award provided by Brain Korea 21 several times, the Young Scientist Award by Seoul National University Hospital and The Best Lecturer at SNU medical school. Dr. Chun has served for the INTERNATIONAL UNION OF PHYSIOLOGICAL SCIENCES (IUPS) as a member of council and a Chair of Genomics and Biodiversity Committee from 2010-2022. Dr. Chun has worked in the field of Hypoxia-inducible factor and the epigenetic transcriptional regulation by jumonji histone demethylase in view of post-translational modification. She published more than 90 papers in the outstanding journal such as Cell Research, JNCI, Cancer research, Oncogene, NAR, Hepatology and Nature Comm. She will talk about how neddylation, a post-translation modification regulates neoplastic and metabolic diseases.
INVITED SPEAKERS

Yun-Sang Lee
Seoul National University, Korea
March 1 (Fri.)

Simplest Glu-Urea-Lys (EUK) for PSMA
* Current Appointments
  - BK Associate Professor, Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University
* Academic Degree
  - Ph.D. 2006 Seoul National University
  - MS 1998 Kyunghee University
  - BS 1996 Kyunghee University
* Field of Specialization
  - Radiochemistry and Radiopharmaceutical
  - Radionanomedicine
  - Molecular Imaging
* Short Scientific Biography
  - Published 66 articles in SCI journals (2001-now).
  - Editorial Board of Nuclear Medicine and Molecular Imaging, Asia Oceania Journal of Nuclear Medicine & Biology.

Dae Yoon Chi
Sogang University, Korea
March 1 (Fri.)

Theranostic Agents for Targeting PSMA: Development of $^{18}$F and Alpha Emitters
Dr. Dae Yoon Chi works in the field organic chemistry, medicine, and PET and SPECT radiopharmaceutical chemistry. He developed many methods for the preparation of radiopharmaceuticals: Halofluorination of F-18 and integrated method for Tc-99m, F-18 fluorination in ionic liquid, and F-18 labeling in protic solvent (Chi-Kim method). Especially, his method shows the mass production of F-18 labeled radiopharmaceuticals on aliphatic position. This method made a possible to register and be used now three new radiopharmaceuticals – F-18 FLT (for lung cancer), F-18 FP-CIT (for Parkinson disease), and F-18 florapronol (Alzheimer disease) – from Korean FDA. These are the first registered PET radiopharmaceuticals officially used after FDG through the clinical trials. He has collaborated extensively with other researchers at Korea and internationally. Meanwhile, He founded FutureChem Co., Ltd. (KOSDAQ 220100) in 1999 and serve until now as a CEO by developing radiopharmaceuticals.
INVITED SPEAKERS

Keon Wook Kang
Seoul National University, Korea
March 1 (Fri.)

Theranostics in Korea
Professor Kang's major fields of expertise are thyroid incidentaloma, functional thyroid disease and radiiodine treatment of thyroid carcinoma. He also has an expertise in nuclear oncology, molecular imaging, nano-medicine and precision medicine. His major fields cover cancer detection using variable radionuclides, based on PET and SPECT imaging technology. He graduated from the Seoul National University and has done his training at the department of internal medicine in the Seoul National University Hospital. Professor Kang's research areas are in vivo molecular imaging of cancer using PET and nanoparticles.

Seigo Kinuya
Kanazawa University, Japan
March 1 (Fri.)

Theranostics in Japan
* Current Appointment
  - Professor, Department of Nuclear Medicine, Kanazawa University, Kanazawa, Japan
  - Vice Director, Kanazawa University Hospital, Kanazawa, Japan
* Education Received
  1. Graduated from Takaoka High School, March 1979
  2. Graduated from School of Medicine, Kanazawa University, March 1986
* Appointments
  1. Instructor, Department of Nuclear Medicine, Kanazawa University from October 1995 to March 2005
  2. Assistant Professor, Department of Nuclear Medicine, Kanazawa University from April 2006 to October 2006
  3. Professor, Department of Nuclear Medicine, Kanazawa University from October 2006
  4. Vice-Director of Kanazawa University Hospital (2012-2014)
  5. Director aide of Kanazawa university Hospital (2014-2016)
  6. Vice-Director of Kanazawa University Hospital (2014-current)
* Editorial Boards
  - Annals of Nuclear Medicine (Associate editor 2005-2008, Editor-in-Chief 2009 - current)
  - Asia Oceania Journal of Nuclear Medicine and Biology (Associate editor 2012 - current)
INVITED SPEAKERS

Feng Wang  
Nanjing Medical University, China  
March 1 (Fri.)

Theranostics in China  
I have a broad background in Nuclear Medicine and Molecular imaging, with specific training and expertise in molecular probe design, and radiolabeling. My research includes apoptosis imaging for the early evaluation of tumor response. As PI or co-Investigator on several National-funded grants (Nature and Science Foundation, China), I laid the groundwork for the proposed research by designing molecular with better bio-distribution and kinetics, and by establishing theranostics and PRRT on NETs and prostate cancer. As president of Society of Nuclear Medicine in Jiangsu province, multi-disciplinary cooperation on NETs, Thyroid cancer and prostate cancer has been established, which will guarantee the completion of this project. In addition, I successfully administered the projects (e.g. staffing, research protections, budget), collaborated with other researchers.
Frank Rösch  
Johannes Gutenberg-University Mainz, Germany

March 1 (Fri.)

SCIENTIFIC SESSION 3-1: NEXT GENERATION THERANOSTICS (FROM CHEMISTS’ POINT OF VIEW) - NOVEL TARGETS AND PROBES

Instant Kit-type Labelling Chemistry for $^{68}$Ga, $^{44}$Sc, $^{177}$Lu.

Frank Rösch holds a professorship at the Institute of Nuclear Chemistry, Johannes Gutenberg-University Mainz, Mainz, Germany. The scientific focus is on physico-chemistry, radiochemistry and radiopharmaceutical chemistry of metallic radionuclides and their compounds in diagnostic and therapeutic application. This covers isotope production including cross sections for different nuclear reaction pathways, and radiochemical separations. The latter included new metallic positron emitters such as $^{86}$Y, $^{94m}$Tc, $^{110m}$In, $^{52}$Mn and others, intended to bridge endoradiotherapy or SPECT with analogous PET-tracers, e.g. aiming at individual radiation dosimetry ($^{90}$Y vs. $^{86}$Y) or quantification of new $^{99m}$Tc tracers by using $^{94m}$Tc-PET.

Several radionuclide generator systems and reactor-based nuclear reactions were investigated leading to no-carrier-added products with potential for therapeutic applications, such as $^{90}$Sr/$^{90}$Y or $^{188}$W/$^{188}$Re and the $^{176}$Yb($n$,Y)$^{177}$Yb-$\beta$$\rightarrow$$^{177}$Lu pathway. In parallel, research covers new radionuclide generator systems, providing positron emitting daughter radionuclides, such as $^{140}$Nd/$^{140}$Pr, $^{72}$Se/$^{72}$As, $^{68}$Ge/$^{68}$Ga and $^{44}$Ti/$^{44}$Sc.

In all cases, radiochemical aspects of generator design and post-processing are accompanied by the synthesis and evaluation of potential PET-radiopharmaceuticals based on trivalent metals or radioarsenic. Currently, all aspects of the $^{68}$Ge/$^{68}$Ga and the $^{44}$Ti/$^{44}$Sc generators are studied systematically, starting from generator concepts, post-processing of generator eluates, new radiolabelling technologies, synthesis of new chelates for $^{68}$Ga and $^{44}$Sc and development and evaluation of new $^{68}$Ga and $^{44}$Sc radiopharmaceuticals such as macrocyclic bisphosphonates, octreotides and urea-glutamate moieties. In this context, DATA- and AAZTA-based chimeric chelators are a current focus, as they allow to label radiopharmaceuticals in an “instant-kit” type protocol – in analogy to $^{99m}$Tc-radiopharmaceuticals. In parallel, the group addresses $^{18}$F-chemistry directed to the synthesis and biological evaluation of $^{18}$F-labelled tracers for studying the human brain. New neurotransmitter analogues such as $^{[18F]}$PR04.MZ and $^{[18F]}$MH.MZ for imaging the dopamine transporter and the serotonin receptor system have been developed.

Henry VanBrocklin  
The University of California, San Francisco, USA

March 1 (Fri.)

Image Guided Therapy: Development of Oncologic and Non-oncologic Agents

Henry VanBrocklin, PhD, is a Professor in Residence, Director of the Radiopharmaceutical Research Program in the Center for Molecular and Functional Imaging (CMFI) at the University of California, San Francisco, USA, and he is a Joint Faculty Scientist at the Lawrence Berkeley National Laboratory. Dr. VanBrocklin obtained his PhD in Radiopharmaceutical Chemistry from Washington University, St. Louis in 1990, and he completed a two-year postdoctoral program at the University of Illinois, Urbana in 1992. He maintains an active radionuclide research program in addition to providing tracers for collaborative basic science and translational clinical research. His research interests include short-lived radioisotope production to the creation of fluorine-18 and carbon-11 labeling chemistry strategies for new radiotracer preparations and applications.
Potential Use of Hypoxia and Thymidine Phosphorylase Imaging Probes for Theranostics

*Profile*
- Affiliation: Central Institute of Isotope Science
- Job Title: Professor
- Degree: Ph.D. of Pharmaceutical Sciences

*Research Keywords*
- Radiopharmaceutical, Molecular Imaging, Nuclear Medicine

*Research Areas*
- Basic nuclear medicine/molecular imaging
- Development of radiopharmaceutical/molecular probe

*Academic Background*
- 1987: Graduate School of Pharmaceutical Science, Kyoto University
- 1985: Faculty of Pharmaceutical Science, Kyoto University
Jae Min Jeong  
Seoul National University, Korea

March 1 (Fri.)

Imaging of the Third Gasotransmitter

* CAREER:  
Jae Min Jeong is a Professor in the Department of Nuclear Medicine, Seoul National University (SNU) College of Medicine since 2005. He graduated from College of Pharmacy SNU in 1982, and had M.Sc. and Ph.D. degrees in the Lab of Biochemistry in the same University. Doctoral thesis was about radiolabeling of monoclonal antibodies and various radiopharmaceuticals with 99mTc. He had Post-Doc in NIH, U.S.A., where he studied about radiolabeling of antibodies and peptides with various radioisotopes under Dr. Chang H Paik’s supervision (1990–1993).

* RESEARCH:  

* SOCIAL ACTIVITY:  
He is the President of Society of Radiopharmaceutical Sciences (SRS) and members of Society of Nuclear Medicine and Molecular Imaging (SNMMI), World Molecular Imaging Society (WMIS), World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), Korean Society of Nuclear Medicine (KSNM), Korean Chemical Society (KCS), Pharmaceutical Society of Korea, etc. He served as a Secretary General of ISRS 2013 in Jeju successfully. He was the founding president of Korean Society of Radiopharmaceuticals and Molecular Probes (KSRAMP, 2014). He is editorial boards of many journals including Nuclear Medicine and Biology and Journal of Nuclear Medicine, and is the first Editor-in-Chief of Journal of Radiopharmaceuticals and Molecular Probes.

* AWARDS:  
Distinguished Service Award by Korean Radioisotope Association (2005); and Nuclear Medicine Academy Award by Korean SNM (2012).
INVITED SPEAKERS

**Cathy S. Cutler**  
*Brookhaven National Laboratory, USA*  
**March 2 (Sat.)**

**Scientific Session 3-2:**  
**Next Generation Theranostics (From Chemists’ Point of View)**  
- Alpha Emitters

**Precision Treatment: Production of Alpha Emitters for Targeted Therapies to Kill Cancer Cells**
Cathy S. Cutler, Ph.D. is Director of the Medical Isotope Research Production and Development group (MIRP) at Brookhaven National Laboratory. Dr. Cutler earned the Bachelor of Sciences in Biochemistry in 1988 and a Doctorate in Inorganic Chemistry in 1993 from the University of Cincinnati with the thesis, Studies at the Interface between Inorganic Chemistry and Nuclear Medicine: Mechanisms of Action of Selected Metal Based Radiopharmaceuticals under the direction of Dr. Ed Deutsch. Dr. Cutler then joined the Radiation Sciences group at Washington University School of Medicine where she worked under the guidance of Dr. Michael J. Welch where she developed and characterized a Ga-68 brain agent that crosses the intact blood brain barrier; designed studies to determine how in vivo metabolism affects compounds distribution, clearance and target selectivity; and collaborated to radionlabel and evaluate peptides containing unique amino acids with modified side chains to bind metals such as technetium, rhenium and rhodium. It was this collaboration that drew Dr. Cutler to the University of Missouri Research Reactor Centers Radiopharmaceuticals Group in 1998. She worked there till June of 2015. The MIRP group at Brookhaven operates the LINAC Isotope Producer (BLIP) that produces both Sr-82 and Ge-68 for commercial production as well as a number of research radioisotopes and is currently evaluating the accelerator production of Ac-225. Additionally, she directs the Target Processing Labs (TPL) that manufactures targets from both the BLIP and isotopes produced off-site for medical applications meeting cGMP. Dr. Cutler’s research focuses on developing production and separation methods for high specific activity radioisotopes, creating a suite of diagnostic and therapeutic agents tailored for individual needs which has been funded by the DOE, NIH, NSF and public foundations. She brings more than 20 years of experience in the development and evaluation of radiopharmaceuticals, utilizing bioinorganic and radioanalytical chemistry to develop and evaluate radiopharmaceuticals for both diagnosis and therapy.
INVITED SPEAKERS

Michael K. Schultz
University of Iowa, USA
March 2 (Sat.)

203Pb/212Pb Peptide Receptor Targeted Theranostics for Cancer
Michael K Schultz PhD is an Associate Professor of Radiology, Pediatrics, Radiation Oncology and Chemistry at the University of Iowa. Dr. Schultz is also founder and Chief Science Officer of Viewpoint Molecular Targeting, Inc. His research and development activities are focused on blending research on cancer biology with radiopharmaceutical development.

Klaus Kopka
German Cancer Research Center, Germany
March 2 (Sat.)

The Heidelberg Series of Glu-ureido based PSMA Tracers: Adaption of Chemical Structure to Clinical Indication
Since the year 2013 Klaus Kopka holds a full professorship position at the Ruprecht-Karls-University of Heidelberg, Germany, and is head of the Division of Radiopharmaceutical Chemistry of the German Cancer Research Center (dkfz) Heidelberg, Germany (http://www.dkfz.de/en/radiochemie/). His research interests focus on Radiopharmaceutical Sciences in combination with Labelling Chemistry and Medicinal Chemistry. In the recent years, the Division of Radiopharmaceutical Chemistry of the DKFZ was mainly focused on the development of the Heidelberg series of novel theranostic radiotracers targeting the prostate-specific membrane antigen (PSMA), i.e. PSMA-617 and PSMA-1007. The clinical translation of such highly promising new radiotracers is very important and can only be realised by state-of-the-art GMP-compliant production on-site, which is implemented in the Division of Radiopharmaceutical Chemistry by available hot labs with clean room environment. Klaus Kopka received his venia legendi (Habilitation) for the field Radiopharmaceutical Chemistry in the year 2007 at the Westfälische Wilhems-University of Münster, Germany. Since the year 2012 he is Chairman of the Working Group Radiochemistry / Radiopharmacy Committee (AGRR) of the German Society of Nuclear Medicine (DGN). The AGRR currently consists of more than 250 members, predominantly scientists from Radiochemistry and Radiopharmacy of Germany, Austria and Switzerland. Klaus Kopka was honoured in the year 2018 together with his colleagues Michael Eisenhut, Matthias Eder und Uwe Haberkorn with the highly recognized “The Stifterverband Science Award – Erwin Schrödinger Prize” of the Helmholtz Association of German Research Centres. Klaus Kopka is author and co-author of more than 150 quotable publications (Web of Science) and inventor and co-inventor of more than 10 patents, mainly dealing with the development of new PET tracers and radiopharmaceuticals for endoradiotherapy. He is the radiopharmaceutical coordinator of the ongoing prospective multi-center clinical trial (>90 patients recruited) within the German Cancer Consortium (DKTK) using [18F]PSMA-11.
Mike Sathekge
University of Pretoria, South Africa

Implementation of Novel Theranostics in Africa
Mike Sathekge is a Professor and Head of Nuclear Medicine department at University of Pretoria. He is Chairman of the Medical Research Council of South Africa. Mike is at the forefront of the specialist training; hence he was honored by being elected as the President of the Colleges of Medicine of South Africa (National Specialist Examining body for all disciplines). Internationally he is the President International Society of Radiolabeled Blood Elements (ISORBE) and past secretary general of the World Federation of Nuclear Medicine and Biology (WFNMB). He has introduced several technologies in the South Africa. Mike’s research efforts in advancing molecular imaging and developing clinical applications have contributed to the clinical and physiological studies on the role of PET/CT on patients suffering from HIV/AIDS and tuberculosis. Prof Sathekge has also introduced peptide receptor radionuclide therapy and peptide radioligand therapy with 68Ga and 225Ac and 177Lu in South Africa and Africa.

Patricia Bernal Trujillo
Fundacion Santa Fe de Bogota, University Hospital, Colombia

Struggles of Theranostics in Latin America
Dr. Patricia Bernal Trujillo is a Nuclear Medicine Physician, head of the Nuclear Medicine Section of the Department of Diagnostic Imaging at University Hospital, Foundation Santa Fe de Bogota, Bogota, Colombia.

M. Fani Bozkurt
Hacettepe University, Turkey

Theranostics Efforts between Europe and Asia
Dr Bozkurt completed his medical training at Hacettepe University Medical School in 1997. He had his residency training at Department of Nuclear Medicine, Hacettepe University Faculty of Medicine between the years 1997 and 2003. He began to work as an academic staff at Department of Nuclear Medicine, Hacettepe University Faculty of Medicine in 2005. Dr Bozkurt underwent a research fellowship program on oncological PET imaging at University of Pennsylvania PET Center in Philadelphia, USA in 2003 and he underwent a visiting scientist program on Cardiac PET imaging at Nuclear Cardiology Department at Harvard University Brigham and Women's Hospital in 2009.
Dr Bozkurt had his associate professorship degree in 2010 and professorship degree in 2019. He was also certified by European Board of Nuclear Medicine.
He has worked as a committee member and a senior advisor at Nuclear Oncology Committee as well as Level 1 Education Chair for ESMIT under EANM. He is currently an executive board member of Turkish Society of Nuclear Medicine.
His areas of main interest are especially nuclear oncology, nuclear cardiology, intraoperative gamma probe applications in nuclear medicine and nuclear medicine theranostic applications, including Y-90 microsphere treatment for hepatic tumors.
INVITED SPEAKERS

Partha Choudhury
Rajiv Gandhi Cancer Institute & Research Centre, India
March 2 (Sat.)

Optimization of Novel Radionuclide Therapies in India
Dr. Partha S. Choudhury is an internationally acclaimed leading Nuclear Medicine Physician of India with special interest in Radionuclide Therapy of various types of cancers. He has more than 25 years of experience in Nuclear Oncology. He is working in Rajiv Gandhi Cancer Institute & Research Centre which is a tertiary level cancer institute of repute with post graduate and super specialty teaching. He is associated with the institute since 1998 and is currently holding the post of Director of the department of Nuclear Medicine. Dr. Choudhury has been instrumental in the institute’s sustained growth over the last 20 years which has one SPECT-CT, two PET-CT scanners and facilities for Radiopharmaceutical Therapy. He has introduced and standardized new procedures in the department both in terms of disease specific diagnostic and molecular imaging & molecular therapy. He is an invited speaker in conferences and symposiums across many countries, the main ones being United Kingdom, Austria, South Africa and South America. He is an avid clinical researcher with publications in peer reviewed journals. He is a technical co-operation consultant of International Atomic Energy Agency (IAEA) Vienna.

Akram Al-Ibraheem
King Hussein Cancer Center, Jordan
March 2 (Sat.)

PSMA PET in Initial Management of Prostate Cancer; Experience from the Arab World
Dr. Al-Ibraheem is currently the president of the Arab Society of Nuclear Medicine (ARSNM) and the President of Jordanian Society of Nuclear Medicine (JOSNM) and the Vice-President of the Asia Oceania Federation of Nuclear Medicine and Biology (AOFNMB).
Dr. Al-Ibraheem has introduced state-of-the art nuclear medicine services to KHCC and Jordan such as DOTATOC and PSMA PET/CT imaging as well as peptide receptors radionuclide therapy (PRRT) and PSMA-ligand radionuclide therapy (PRLT). Dr. Al-Ibraheem has authored and published many articles in international peer-reviewed journals focusing on molecular imaging and the role of PET/CT in cancer management as well as theranostics and he is an editorial board member of many international journals. He has served as an expert for the IAEA in several missions since 2012.
INVITED SPEAKERS

Mark Konijnenberg
Erasmus Medical Center, The Netherlands
March 2 (Sat.)

Prospective Dosimetry Options for Alpha-emitter Targeted Therapy
* 1977-1983: Study experimental physics at the University of Amsterdam
* 1984-1990: PhD research at the Energy research Centre Netherlands on the topic: Exchange currents in the radiative capture of thermal neutrons by protons and deuterons.
* 1990: PhD-exam in nuclear physics at the Technical University Delft, Netherlands
* 1990-1994: Post-Doc research at the Dutch Cancer Institute in Amsterdam on radiation dosimetry and treatment planning for Boron Neutron Capture Therapy facility.
* 1994-2010: Scientist and dosimetry expert for Mallinckrodt Medical BV in Petten, Netherlands. Responsible for dosimetry dossier diagnostic agents and development of dosimetry techniques for radionuclide therapy, e.g. radiosynovectomy with 153Sm HA, bone pain palliation with 186Re HEDP, radionuclide therapy with 90Y-DOTA-Octreotide and 177Lu-DOTA-Octreotate.
* 2010-present: Physicist at the nuclear medicine department of the Erasmus Medical Centre in Rotterdam, Netherlands. Responsible for dosimetry in radionuclide therapy applications of pre-clinical and clinical developments.
* 2007-present: Member (chair from Oct. ’14) of the EANM dosimetry committee

Arun Gupta
BPKIHS, Nepal
March 2 (Sat.)

Voxel-based Dosimetry of $^{177}$Lu-IONPs-folate using SPECT/CT Imaging of Mice
Arun Gupta, PhD, is a permanent faculty of Radiological Physics and Medical Imaging in the department of Radiodiagnosis and Imaging, B.P. Koirala Institute of Health Sciences (BPKIHS), Dharan, Nepal. He received his bachelor’s degree in Medical Imaging Technology from BPKIHS, Nepal in 2007. He then obtained his Master’s degree in Nuclear Medicine from All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2010. In 2010, he passed certification examination of Radiation Safety Officer (RSO) from Bhabha Atomic Research Center (BARC), Mumbai, India and worked as RSO in a PET/CT center in New Delhi, India for several months. He then started working as RSO cum Medical Physicist in the department of Radiodiagnosis and Imaging, BPKIHS, Nepal since December 2010. Later, he joined as Senior Demonstrator and RSO in the same department in BPKIHS. Since his joining in BPKIHS, he has been involved in teaching radiological physics to UG and PG students and taking care of radiation safety in the institute.
INVITED SPEAKERS

**Jae Sung Lee**  
*Seoul National University, Korea*  
March 2 (Sat.)

**New Approaches to Fast Voxel-based Dosimetry**

Jae Sung Lee received his bachelor’s degree of electrical engineering and PhD of biomedical engineering from Seoul National University (SNU), Seoul, Korea in 1996 and 2001, respectively. He then worked as a postdoctoral fellow of radiology at John Hopkins University. In 2005, he joined SNU College of Medicine where he is currently a professor of nuclear medicine and biomedical sciences. His early academic achievements are mainly related with the PET/SPECT imaging studies for understanding the energetics and hemodynamics in brain and heart. The most notable achievement of Dr. Lee’s group since the foundation of his own lab in SNU is the development of PET systems based on a novel photo-sensor, silicon photomultiplier (SiPM). He has published 8 book chapters and over 250 papers in peer-reviewed journals and received multiple research awards from various scientific societies. He is the editor-in-chief of Biomedical Engineering Letters (BMEL) and serves as editorial and advisory board members for several other international scientific journals. In 2013 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC), he was the MIC program chair. He is currently the chair of the Nuclear and Medical Imaging Sciences Council of the IEEE Nuclear and Plasma Sciences Society (IEEE NPSS).

**Makoto Hosono**  
*Kindai University, Japan*  
March 2 (Sat.)

**ICRP Perspectives for Individualized Radionuclide Therapy**

Makoto Hosono, MD, PhD, is Professor of Institute of Advanced Clinical Medicine and Department of Radiology, Kindai University, Osaka, Japan, and serves as a member of ICRP C3 since 2017. After graduating from Kyoto University School of Medicine, Japan, he has been contributing to the fields including nuclear oncology, tumor targeting, and radiation protection as well as neurology and cardiology. He serves as the Chair of PET Committee since 2011 and as an active member of Radionuclide Therapy Committee of Japanese Society of Nuclear Medicine (JSNM). He also served as the Chief of Working Group for establishment of National Diagnostic Reference Levels in 2015 (Japan DRLs 2015) for diagnostic radiology and nuclear medicine by organizing cooperation among radiology-related academic and professional organizations in the framework of Japan Network for Research and Information on Medical Exposure (J-RIME). Since 2017, he is the Chief of J-RIME. He has been the principal Investigator of a Research Group on Radiation Protection in Medicine of Ministry of Health in Japan since 2007. He was responsible for the clinical trials of Ra-223 dichloride in Japan as one of principal investigators since 2011. He has participated in numerous educational activities for PET and SPECT oncology imaging and radionuclide therapy at national and international events.
Lingeswaran Kasilingam  
* Consultant Physician, Nuclear Medicine  
  - MD (USM), M.MED (Nuclear Medicine) (USM), AM (Mal), Fellowship in Nuclear Oncology (Australia)  
* Specialisation  
  - General Nuclear Medicine imaging  
  - Molecular imaging (PET-CT & SPECT-CT)  
  - Nuclear Oncology and targeted radionuclide therapy  
* Awards and Achievements  
  - The only Consultant Nuclear Medicine Physician expertly-trained in administering $^{177}$Lu-PSMA treatment in Malaysia  
  - Over 10 publications, journals, local and international conferences in Nuclear Medicine  
  - Invited speaker for multiple local and regional conferences

Hendra Budiawan  
Hasan Sadikin Hospital, Bandung, Indonesia  
March 2 (Sat.)

Hendra Budiawan has been doing clinical practices in gamma camera imaging and radionuclide therapy since 2004 and PET imaging since 2011. His current main interests are oncology PET imaging and radionuclide therapy.

Pham Cam Phuong  
Bach Mai Hospital, Vietnam  
March 2 (Sat.)

* Current Appointments: Vice Director of The Nuclear Medicine and Oncology Center, Bach Mai Hospital  
* Diploma:  
  - 2001 General Doctor  
  - 2006 Resident Doctor of Oncology at Ha Noi Medical University  
  - 2007 Resident Doctor of Oncology at Pierre - Marie Curie University (Paris IV), France  
  - 2014 PhD. of Oncology of Ha Noi Medical University  
  - 2018 Associate Professor at Ha Noi Medical University  
* Field of Specialization: Nuclear Medicine and Oncology
INVITED SPEAKERS

Shamim Momtaz Ferdousi Begum  
National Institute of Nuclear Medicine & Allied Sciences, Bangladesh  
March 2 (Sat.)

Prof. Dr. Shamim Momtaz Ferdousi Begum graduated from Rajshahi Medical College in 1988. She joined in Bangladesh Atomic Energy Commission in 1990. She obtained her fellowship from Asian Board of Nuclear Medicine in 2016 and Diploma in Nuclear Medicine (DNM) from University of Dhaka in 1993. Currently she has been working as Professor of Nuclear Medicine and assigned as head of PET-CT Division of NINMAS. She is faculty member of NINMAS and editorial board member of Bangladesh Journal of Nuclear Medicine. She is engaged in several international, national projects and research works. She is national project counterpart of several IAEA TC projects, local coordinator and advisor of KOICA projects. She presented more than 25 abstracts at national and international meetings and published more than 50 papers in peer-reviewed journals. She has supervised about eight post graduated theses.

Noboru Oriuchi  
Fukushima Medical University, Japan  
March 2 (Sat.)

* Current Affiliation Organization: Duty, Fukushima Global Medical Science Center, Advanced Clinical Research Center, Professor  
* Graduate School: Gunma University, Graduate School, Division of Medical Sciences, Doctor's Course, Completed, JAPAN, 1991.03  
* Academic Society Affiliations: SNM, UNITED STATES  
* Field of Expertise (Grants-in-aid for Scientific Research classification): Radiation Science

Ting Kun Au Yong  
Queen Elizabeth Hospital, Hong Kong  
March 2 (Sat.)

Dr TK Au Yong graduated from the Faculty of Medicine of the University of Hong Kong in 1987 and joint the Department of Nuclear Medicine of Queen Elizabeth Hospital of Hong Kong on 1990. He obtained the Master of Science in Nuclear Medicine of the University of London in 1994, and then fellowships in Nuclear Medicine of Hong Kong College of Radiologists and Hong Kong Academy of Medicine in 2015. He is now the consultant-in-charge of the NM department and Clinical PET Centre of QEH. He is the President of Hong Kong Society of Nuclear Medicine in 1999-2003 and the Hong Kong Society of Nuclear Medicine and Molecular Imaging from 2018. He is also the Treasurer of the Hong Kong Society of Clinical PET. He served and the council member of the Hong Kong College of Radiologists and is now the network training program director of nuclear medicine of the College. He has special interest include Nuclear Oncology, Nuclear Cardiology and radionuclide therapy.
INVITED SPEAKERS

David Ng

*Singapore General Hospital, Singapore*

**TEIN LUNCHEON SEMINAR**

March 2 (Sat.)

Dr David Ng completed post-graduate medical training in both Internal Medicine and Nuclear Medicine. He was awarded a Training Fellowship to the Clinical PET Centre, Guy’s, St Thomas’ and Kings’ Hospital, University of London and to the Hospital of the University of Pennsylvania, Philadelphia, USA.

He is currently Head and Senior Consultant at the Department of Nuclear Medicine and Molecular Imaging, Division of Radiological Sciences, Singapore General Hospital, Senior Clinical Lecturer with the National University of Singapore Yong Loo Lin School of Medicine and an Associate Professor at the Duke-NUS Medical School. He is also Deputy Vice Chair of Clinical Quality in the Radiological Sciences Academic Clinical Programme. He is currently the President of the Nuclear Medicine Society (Singapore) and a past Chair of the Chapter of Nuclear Medicine in the College of Radiologists, Singapore.

Hong Zhang

*Shanxi Medical University, China*

**TEIN LUNCHEON SEMINAR**

March 2 (Sat.)

Prof. Hong ZHANG is a Distinguished Professor of Zhejiang University, top-3 university in China, specialized in nuclear medicine and molecular imaging. He also serves as Chair of Department of Nuclear Medicine at the Second Affiliated Hospital of Zhejiang University School of Medicine, Director of Institute of Nuclear Medicine and Molecular Imaging, Assistant Dean of Zhejiang University School of Medicine, and Vice President of Shanxi Medical University.

Prof. Hong ZHANG is also the Distinguished Young Scholar of National Natural Science Foundation of China (NSFC) and Principal Investigator of the National Key Research and Development Program of China. He received his Doctoral Degree in Diagnostic Radiology and Nuclear Medicine at Gunma University School of Medicine in Japan, and received the PhD training at St. Bartholomew’s Hospital of the University of London in UK, and a postdoctoral fellow supported by the Japan Society for the Promotion of Science (JSPS) in Japan. From 2002-2004, Dr. Hong Zhang has been working at the National Institute of Radiological Sciences (NIRS) in Japan.

His research focuses on functional diagnostic imaging in neurology, oncology, stem cell and gene imaging.
INVITED SPEAKERS

Humayun Bashir
Shaukat Khanum Memorial Cancer Hospital & Research Centre, Pakistan
March 2 (Sat.)

* Designation: Consultant & Head of Nuclear Medicine Department
* Institute/Organization: Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, PAKISTAN

Nuclear medicine physician with 20 years of experience in the specialty acquired in Pakistan, United Kingdom and Saudi Arabia. Special interest in hybrid scintigraphy and theranostics. Has authored over 25 indexed publications with over a hundred citations.
- Fellow of the College of Physicians and Surgeons Pakistan (Pk)
- Fellow of the Royal of College Physicians of Edinburgh (UK)
- Fellow of the Royal of College Physicians London (UK)
- Fellow of the European Board of Nuclear Medicine (EU)
- Diplomate of the Certification Board of Nuclear Cardiology: 2006-16 (USA)

Henri Becquerel Fellowship in Pediatric Nuclear Medicine from UK

Member Board of Directors of the Asia Oceanic Federation of Nuclear Medicine and Biology (AOFNMB)
Immediate past president of the Pakistan Society of Nuclear Medicine (2015-17)
Chairman for the 18th Shaukat Khanum Cancer Symposium (November 1-3, 2019)

Patricia Bautista
St. Luke’s Medical Center, Philippines
March 2 (Sat.)

- Diplomate (since 2012) and Fellow (since 2014), Philippine Society of Nuclear Medicine
- Fellow (since 2017), Asian Nuclear Medicine Board
- Certified Clinical Densitometrist
- Pioneer of Theranostics in the Philippines after having trained at Zentralklinik Bad Berka, Germany from July to September 2016
- Board Director and Head of Residency Training Council (since 2017), Philippine Society of Nuclear Medicine
- Editor-in-Chief (since 2015), Philippine Journal of Nuclear Medicine
- Residency Training Officer (since 2018) of the Department of Nuclear Medicine and PET Center, St. Luke’s Medical Center – Global City
- Nuclear Medicine Consultant at St. Luke’s Medical Center – Global City and Quezon City (since 2012) and National Kidney and Transplant Institute (since 2018), among other affiliations
INVITED SPEAKERS

Anna Wu
Beckman Research Institute of the City of Hope, USA
March 2 (Sat.)

Antibody Theranostics
Professor and Chair, Department of Molecular Imaging and Therapy
Professor, Department of Radiation Oncology
Co-Director, Center for Theranostics Studies
Beckman Research Institute of the City of Hope
Duarte, CA 91910

Education:
Ph.D., Molecular Biophysics and Biochemistry, Yale University, New Haven, CT
A.B., Biochemical Sciences, Harvard University, Cambridge, MA

Professional Societies:
American Association for Cancer Research
American Society for Clinical Oncology
Society of Nuclear Medicine and Molecular Imaging
Society for Immunotherapy of Cancer
World Molecular Imaging Society

Young Kee Shin
Seoul National University, Korea
March 2 (Sat.)

In Vitro to in Vivo Companion Diagnostics
Dr. Young Kee Shin is interested in developing the promising New Molecular Entity (NME), including antibody, siRNA, small molecule that targets cancer and other diseases. From these candidates, he aims to propose proof-of-concept. Death Valley, which must be overcome for the development of new drugs, is a stage in basic science that progresses into clinical research and difficulty in actual clinical application when clinical trials are completed and commercialized. In order to achieve this, we delve deeply in researching biomarkers, regulatory science, exploratory clinical trials. Additionally, approaching from a different perspective, drug economics considering cost-effectiveness is also critical. From these, we can ultimately develop new drugs with corporations. Noteworthily, Dr. Young Kee Shin is a pioneering researcher in the field of companion diagnosis. Being the head of companion diagnosis enterprise organization, he developed kits that can detect genetic mutations in breast cancer, lung cancer and colon cancer. He also transferred patents and technologies to the industry’s leading companies. In addition, he participated two of the initial tasks including authorization and screening of Food and Drug Administration’s the ‘In Vitro Companion Diagnostic Devices.’ From this, he developed technologies and policies in the field of companion diagnosis which upgraded the techniques of the field.
INVITED SPEAKERS

Jung-Joon Min
Chonnam National University, Korea
March 2 (Sat.)

**Bacteria-based Radio-theranostics**

* Education and Training
  - 1999-2002: Ph.D. in Nuclear Medicine and Molecular Imaging, Chonnam National University, Gwangju, Korea
  - 1996-1998: M.S. in Nuclear Medicine, Chonnam National University, Gwangju, Korea
  - 1985-1991: M.D. in Medical Science, Chonnam National University Medical School, Gwangju, Korea

* Professional Experiences
  - 2017-present: Chair of Department of Nuclear Medicine, Chonnam National University Medical School, Gwangju, Korea
  - 2011-present: Professor of Nuclear Medicine, Chonnam National University Medical School, Gwangju, Korea
  - 2006-2001: Associate Professor of Nuclear Medicine, Chonnam National University Medical School, Gwangju, Korea
  - 2004-2006: Assistant Professor of Nuclear Medicine, Chonnam National University Medical School, Gwangju, Korea

Andrei Iagaru
Stanford University, USA
March 2 (Sat.)

**Gastrin-Releasing Peptide Receptors for Theranostics in Prostate Cancer**

Dr. Iagaru is a Professor of Radiology - Nuclear Medicine and the Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University Medical Center. He completed medical school at Carol Davila University of Medicine, Bucharest, Romania, and an internship at Drexel University College of Medicine, Graduate Hospital, in the Department of Medicine in Philadelphia. He began his residency at the University of Southern California (USC) Keck School of Medicine, Los Angeles, in the Division of Nuclear Medicine, where he was the chief resident. Dr. Iagaru finished his residency and completed a PET/CT fellowship at Stanford University's School of Medicine in the Division of Nuclear Medicine. His research interests include PET/MRI and PET/CT for early cancer detection; clinical translation of novel PET radiopharmaceuticals; peptide-based diagnostic imaging and therapy; targeted radionuclide therapy.

Over the past twelve years since joining the faculty at Stanford, Dr. Iagaru has received several awards including the Society of Nuclear Medicine (SNM) 2009 Image of the Year Award; AuntMinnie 2016 Best Radiology Image, American College of Nuclear Medicine (ACNM) Mid-Winter Conference 2010 Best Essay Award; 2009, 2014 and 2015 Western Regional SNM Scientist Award; 2011 SNM Nuclear Oncology Council Young Investigator Award; and a Stanford Cancer Center 2009 Developmental Cancer Research Award in Translational Science. Dr. Iagaru presented more than 200 abstracts at national and international meetings and published more than 130 papers in peer-reviewed journals, as well as 7 book chapters and 1 book.
Michael Kreissl
University Hospital Magdeburg, Germany

Theranostics in Combination with Local Therapies
Michael C. Kreissl graduated from the Medical School of Julius-Maximilians University Würzburg, Germany in 2000. He then worked as a medical resident in the Department of Nuclear Medicine at the University Hospital Würzburg until 2003. He then took the position as a postdoctoral research fellow in the Department of Molecular and Medical Pharmacology under the supervision of Dr. Heinz Schelbert working in the field of cardiovascular molecular imaging. In 2005, he returned to Würzburg to complete his residency. He became attending physician in 2007. In 2012 he moved on to Augsburg Central Hospital as vice director of Nuclear Medicine. Continuing teaching and research in Würzburg, he was appointed assistant professor of Nuclear Medicine in 2014. Since 2017 he is Professor of Nuclear Medicine and heading the division of Nuclear Medicine at Otto-von-Guericke University Magdeburg, Germany. He has a strong academic and clinical focus on imaging the endocrine system, theranostics, hybrid imaging and local as well as thyroid therapy. His early academic achievements are mainly related to imaging the endocrine system and endocrine tumors. Among other functions he is board member of the International Research Group on Immuno-Scintigraphy and Therapy (IRIST) and member of the member of the advisory council of thyroid section of the the German Society of Endocrinology and member of the EORTC Endocrine Group.

Wolfgang Weber
Technical University of Munich, Germany

PSMA Targeting Alpha Therapies
Wolfgang Weber, MD is Professor and Chair of the Department of Nuclear Medicine at the Technical University of Munich in Germany (TUM). Dr. Weber is a graduate of the TUM Medical School. He was trained in Nuclear Medicine at TUM and joined the faculty of the Department of Nuclear Medicine at TUM in 2001. From 2004-2007, he was Associate Professor at the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA). In 2007 he was appointed Professor and Chair of the Department of Nuclear Medicine at the University of Freiburg in Germany. In 2013 he returned to the USA and became Chief of Nuclear Medicine at the Memorial Sloan Kettering Cancer Center as well as Professor of Radiology at the Weill Cornell Medical College. He held both positions until the end of 2017. Dr. Weber's research is focused on molecular imaging of cancer for planning and monitoring of therapeutic interventions. He is also interested in targeted radionuclide therapy of cancer and theranostics. Dr. Weber has published more than 250 papers in leading scientific journals including the Journal of Clinical Oncology, PNAS as well journals of the Nature series. He has served on the editorial board of several scientific journals such as the Journal of Nuclear Medicine, European Journal of Nuclear Medicine and Molecular Imaging, Clinical Cancer Research and Journal of Clinical Oncology.
INVITED SPEAKERS

**Il Minn**  
Johns Hopkins University, USA  
March 2 (Sat.)

**Scientific Session 5-2: Next Generation Theranostics (From Physicians’ Point of View)**

**Immune Cell-based Theranostics**

Dr. Minn is an assistant professor in Russel H. Morgan Department of Radiology and Radiological Science and an associate member of Institute for NanoBioTechnology (INBT) at Johns Hopkins University. Dr. Minn’s main research interest is to develop research and theranostics tools for various human diseases using synthetic biological approaches. He has been developing molecular-genetic theranostics for cancer and other diseases, which include synthetic promoters, clinically compatible non-viral expression vectors, synthetic reporters, and safe and efficient nanoparticles for in vivo gene delivery. He has recently developed new reporter system for non-invasively imaging of chimeric antigen receptor T cells with high specificity and sensitivity.

**Steve Yoon-Ho Cho**  
University of Wisconsin - Madison, USA  
March 2 (Sat.)

**Scientific Session 5-2: Next Generation Theranostics (From Physicians’ Point of View)**

**Imaging Criteria for Assessing Response to Theranostics – Challenges and Opportunities**

Dr. Steve Y. Cho, M.D. is an Associate Professor in the Nuclear Medicine and Molecular Imaging Section of the Department of Radiology at the University of Wisconsin - Madison. He is engaged in translational molecular imaging and theranostics research as Director of the Radiopharmaceutical Production Facility (RPF), Director of the UW Carbone Cancer Center Imaging Core and Associate Director of the UW PET Imaging Center. His research interest involves translational PET imaging to improve clinical management and therapy development for cancer with special interest in PSMA based agents for prostate cancer and lymphoma.

Dr. Cho graduated from the New York University School of Medicine in the Research Honors Program, and received prior medical training through a Pediatrics Residency and a Pediatric Hematology/Oncology Fellowship from the Johns Hopkins Hospital. After a Clinical Pharmacology Fellowship at the National Institutes of Health, inspired by the promise of molecular imaging, he underwent further training with a Nuclear Medicine Residency and PET Fellowship at Johns Hopkins Hospital. He stayed on at Johns Hopkins as an Assistant Professor of Radiology and Oncology before moving to UW–Madison in 2014. Dr. Cho was the recipient of the 2008 RSNA Research Scholar Award, 2008 Prostate Cancer Foundation (PCF) Young Investigator Award, 2011 PCF Creativity Award, and 2013 Society of Nuclear Medicine Editors’ Choice Award for the top three best clinical investigation manuscripts.
INVITED SPEAKERS

Josh Mailman
NorCal CarciNet Community, USA
March 2 (Sat.)

USA Experiences
Diagnosed with PNET in 2007. First PRRT in Bad Berka in May 2009. Josh has an MBA from the Anderson School of Management at UCLA and has been a technology entrepreneur for over 20 years having co created eFax.com. Currently Josh is the President of the NorCal CarciNET Community and Past Chairperson of the Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging. Josh is a patient advocate and former executive board member of the Society for Integrative Oncology (SIO) and was named SIO Patient Advocate of Year in 2010. Josh is a member of the National Cancer Institute's Steering Committee on GI Cancers. Josh serves on the following boards, World Association of Radiopharmaceutical Molecular Therapy, the NeuroEndocrine Tumor Research Foundation, the Education and Research Foundation for Nuclear Medicine and Molecular Imaging and the North America Neuroendocrine Tumor Society's Advisory Board. In 2015 Josh was honored for his work in the NETs and nuclear medicine with the SNNMI President’s award community with the award for distinguished service and the Warner Advocacy Award for NETs.

Song-hoon Ham
Korea
March 2 (Sat.)

Korean Experiences

Yoshiyuki Majima
NPO PanCAN, Japan
March 2 (Sat.)

Japanese Experiences
President, NPO Pancreatic Cancer Action Network Japan (PanCAN Japan)
* Board/Committee Membership
- International Neuroendocrine Cancer Alliance, Director
- Japan Federation of Cancer Patient Groups, Director
- Rare Cancers Japan, President
- Nuclear Medical Treatment Promotion National Congress Vice President
- Patient Advisory Board Member of the Japan Pharmaceutical Manufacturers Association
- National Cancer Center East Hospital Institutional Review Board Member
Beat Löffler studied Communication Sciences, Philosophy and Political Science. He received an MA at Freie Universität Berlin and improved himself in Life Sciences / Biology for further 2 years. He absolved the training course of the European Center of Pharmaceutical Medicine. In 1983 he started his first company for concepts and new media. Six years later, he became Director of the International Hightech Forum of the Swiss Industries Fair. After working for further 6 years in the new technology sector as developer and conference organizer, creating concepts for emerging technology events, he started in 1994 his present company “L&A Concept Engineering” and specialized in the fields of the development of innovation concepts and of science and knowledge promotion initiatives as well as in leadership training and interdisciplinary bridging events.

Fields of work are • Computational Fluid Dynamics • Materials Science • Energy Technology and • Life Sciences. Beat Löffler held numerous mandates for projects developed by his company, e.g.: He wrote and developed the “BioValley Upper Rhine Network-Initiative” and coached it for 6 years as Secretary General, He signed responsible for the Trade Fair for Simulation and Visualization SIMPAT and developed the Leadership Training EUROPRENEUR together with INSEAD, Fontainebleau and HSG, St. Gallen. He had a mandate during 4 years of the Centre Européen de Management in Colmar. He spent 4 years as life science business development-consultant with lead EMEA for the Japanese company NEC High Performance Computing. In 2005, he conceived and realized the European Summit for New Materials in Energy and Mobility in Essen, Germany for “Initiativkreis Ruhr”. He concepted and realized the First World Summit for New Materials in Energy Technology in Lisbon, 2006. In the same year, he started the development of a concept for a conference for applied Nanomedicine. In 2007, he founded together with Patrick Hunziker, MD, the European Foundation for Clinical Nanomedicine, started up the European Society for Nanomedicine and cofounded the International Society for Nanomedicine. Since 2007, he is CEO of the CLINAM Foundation and Secretary General of the European Society for Nanomedicine and the International Society for Nanomedicine. 2014 he received from the University of Basel an honorary doctor of medicine. His own company has developed in the last 5 years towards new fields and includes Nanotechnology in Health and energy supply. A novel project is on plastic substitution. Beat Löffler signs responsible for the European Summits for Clinical Nanomedicine and Targeted Medicine, which is since 5 years in Europe the largest platform for this discipline. He has lead as disseminator several EU-funded Projects such as leading “DiscoGnosis”, “Nanomed2020” and “NanoAthero”
INVITED SPEAKERS

Dong Soo Lee
Seoul National University, Korea
March 3 (Sun.)

Introduction to Radionanomedicine
As a nuclear medicine physician, I am interested in brain studies and radionanomedicine. In the early days, I was involved in nuclear cardiology, brain mapping and molecular imaging sequentially in my carrier since I started nuclear medicine in 1990 as faculty in Seoul National University and Seoul National University Hospital, Korea. Finally now I study brain connectivity using PET/MRI which are based on topological interpretation of the group PET and individual resting-state MRI. Recently, moving from molecular imaging to nanomedicine and theranostics, I just published a book by Springer, ‘Radionanomedicine; combined nuclear and nanomedicine’. I believe that radionanomedicine is the way how nanomedicines (nanodrugs or nanomaterials) enter into the clinical discipline. I am currently taking the role of President of World Federation of Nuclear Medicine and Biology (2019-2020) and also joining International Society for Nanomedicine working as Vice-President.

Weibo Cai
University of Wisconsin - Madison, USA
March 3 (Sun.)

Radiolabeled Nanomaterials
Weibo Cai is a Vilas Distinguished Achievement Professor of Radiology, Medical Physics, Biomedical Engineering, Materials Science & Engineering, and Pharmaceutical Sciences at the University of Wisconsin - Madison, USA. He received a BS degree in Chemistry from Nanjing University, China (1995) and a PhD degree in Chemistry from the University of California, San Diego (2004). Between 2005 and 2008, Dr. Cai did his post-doctoral research in the Molecular Imaging Program at Stanford (MIPS). In February 2008, Dr. Cai joined the University of Wisconsin - Madison as a Biomedical Engineering Cluster Hire, and was promoted to Associate Professor with Tenure in 2014, and Full Professor in 2018. Dr. Cai’s research at UW-Madison (http://mi.wisc.edu) is primarily focused on molecular imaging and nanotechnology.

Dr. Cai has authored >280 peer-reviewed articles and his publications have been cited >20,000 times with an H-index of 72. Dr. Cai has received many awards, including the Society of Nuclear Medicine and Molecular Imaging (SNMNI) Young Professionals Committee Best Basic Science Award (2007), the European Association of Nuclear Medicine (EANM) Springer Prize (2011 & 2013), American Cancer Society Research Scholar (2013-2017), EANM Annual Congress Plenary Lecturer (2016), UW-Madison Vilas Distinguished Achievement Professor Award (2017), Inaugural Nano Research Young Innovators (NR45) in Nanobiotechnology Award (2018), Nano-Micro Letters (NML) Researcher Award (2018), Chinese Society of Nuclear Medicine (CSNM) Annual Meeting Plenary Lecturer (2018), Fellow of American Institute for Medical and Biological Engineering (AIMBE, 2018), among others.

Dr. Cai has served on the Editorial Board of >20 scientific journals (e.g. Theranostics, Journal of Nuclear Medicine, European Journal of Nuclear Medicine and Molecular Imaging, Molecular Pharmaceutics, Scientific Reports, American Journal of Cancer Research, American Journal of Translational Research, etc.), performed peer review for >130 journals, and participated in many grant review panels. What he is most proud of is that his trainees at UW - Madison have received ~100 awards to date, such as the 2012 Berson-Yalow Award from SNMMI, multiple Young Investigator Awards from SNMMI, 2015 EANM Eckert & Ziegler Abstract Award, among others.
INVITED SPEAKERS

Seung-Hoon Lee

Seoul National University, Korea

March 3 (Sun.)

Ceria-based Nanoparticle Therapy against ROS-mediated Injury

Dr. Seung-Hoon Lee is the professor of Neurology in Seoul National University Hospital. His area of clinical practice is cerebrovascular disease which include stroke, arteriovenous malformation, aneurysm and cerebral atherosclerosis, but has shown outstanding performance in both clinical and basic research. In the recent years, he published a lot of research works on clinical stroke research and basic research using nanomedicine in Angewandte Chemie, Annals of Neurology, Nano Research, Neurology, and Stroke. At 2016, he founded a startup corporation, Cenyx Biotech Inc. Since then, he have tried to apply a new nanomedicine approach to a clinical filed especially with ceria-based nanomaterials.

He also held the president of the Korea Cerebrovascular Research Institute.

1996  MD, Seoul National University College of Medicine
2001  MS, Seoul National University College of Medicine
2006  PhD, Seoul National University College of Medicine
2005 – current  Professor, Seoul National University Hospital
2016 – current  CEO, Cenyx Biotech Inc
2017 – current  President, Korean Cerebrovascular Research Institute

Ren-Shyan Liu

Taipei Veterans General Hospital, Taiwan

March 3 (Sun.)

Theranostics of Exosomes on Alzheimer’s disease

* 2018-present:
  - Director, Dept. of Nuclear Medicine & PET Center, Cheng Hsin General Hospital
  - Professor, School of Medicine and School of Biomedicine and Engineering, National Yang-Ming University
  - Special Faculty Doctor, Dept. of Nuclear Medicine, National PET/Cyclotron Center, Taipei Veterans General Hospital

* Specialty:
Molecular-Genetic Imaging of Small Animal, Nuclear Oncology, Neuronuclear Medicine, Nuclear Endocrinology, Emergency Medical Planning and Management of Radiation Accident
INVITED SPEAKERS

Wen-Sheng Huang
Taipei Veterans General Hospital, Taiwan
March 3 (Sun.)

* Current Position: Chairman, Dept. Nucl. Med. & National PET/Cyclotron Ctr. Taipei Veterans General Hospital (TVGH), 2016/1/16 - current
He also appoints as a committeeman of Ministry of Examination ROC; National delegate of AOFNMB, Regional delegate of ASNM; Executive Director, Taiwan SNM (TSNM), Taiwan Mol. Imaging Soc.; Taiwan Chinese- Western Med. Soc.; Committeeeman, Nat. Health Care Bureau; Higher Edu. Evaluation & Accreditation Council of Taiwan & Executive Supervisor, Taiwan Society of Neutron Capture Therapy Society. His main res. areas include nucl med. & mol imaging, thyroidology, radiation protection & radionuclide therapy. His major experiences include Depart. Chief, NM, Tri-Service General Hospital (TSGH); Committeeeman of Hosp. Evaluation & Accreditation Committee for NM Specialty, TSNM, Exam. Yuan, R.O.C.; Chief editor, Ann. NMMI, Taiwan, President, Secretary Gen. & Vice President, Chief Committeeeman of Board Exam. of TSNM. Superintendent, Thyroid e-Hosp; Chief, Mol. Imaging Ctr., Co-chief, Depart. NM & Med. Res., Changhua Christian Hospital. He used to being a visiting scholar: Med. Edu. & Pub. Health, USC & UCI; Thyroid Lab., Long Beach VA Med. Ctr. USA. He has published more than 50 peer-reviewed SCI papers since 2012.

Lingeswaran Kasilingam
Beacon Hospital, Malaysia
March 3 (Sun.)

* Consultant Physician, Nuclear Medicine
- MD (USM), M.MED (Nuclear Medicine) (USM), AM (Mal), Fellowship in Nuclear Oncology (Australia)
* Specialisation
- General Nuclear Medicine imaging
- Molecular imaging (PET-CT & SPECT-CT)
- Nuclear Oncology and targeted radionuclide therapy
* Awards and Achievements
- The only Consultant Nuclear Medicine Physician expertly-trained in administering 177Lu-PSMA treatment in Malaysia
- Over 10 publications, journals, local and international conferences in Nuclear Medicine
- Invited speaker for multiple local and regional conferences

Hendra Budiawan has been doing clinical practices in gamma camera imaging and radionuclide therapy since 2004 and PET imaging since 2011. His current main interests are oncology PET imaging and radionuclide therapy.
INVITED SPEAKERS

Pham Cam Phuong  
Bach Mai Hospital, Vietnam  
March 3 (Sun.)

* Current Appointments: Vice Director of The Nuclear Medicine and Oncology Center, Bach Mai Hospital  
* Diploma:  
  - 2001 General Doctor  
  - 2006 Resident Doctor of Oncology at Ha Noi Medical University  
  - 2007 Resident Doctor of Oncology at Pierre - Marie Curie University (Paris IV), France  
  - 2014 PhD. of Oncology of Ha Noi Medical University  
  - 2018 Associate Professor at Ha Noi Medical University  
* Field of Specialization: Nuclear Medicine and Oncology

Shamim Momtaz Ferdousi Begum  
National Institute of Nuclear Medicine & Allied Sciences, Bangladesh  
March 3 (Sun.)

Prof. Dr. Shamim Momtaz Ferdousi Begum graduated from Rajshahi Medical College in 1988. She joined in Bangladesh Atomic Energy Commission in 1990. She obtained her fellowship from Asian Board of Nuclear Medicine in 2016 and Diploma in Nuclear Medicine (DNM) from University of Dhaka in 1993. Currently she has been working as Professor of Nuclear Medicine and assigned as head of PET-CT Division of NINMAS. She is faculty member of NINMAS and editorial board member of Bangladesh Journal of Nuclear Medicine.  
She is engaged in several international, national projects and research works. She is national project counterpart of several IAEA TC projects, local coordinator and advisor of KOICA projects. She presented more than 25 abstracts at national and international meetings and published more than 50 papers in peer-reviewed journals. She has supervised about eight post graduated theses.
INVITED SPEAKERS

**Patricia Bautista**  
*St. Luke’s Medical Center, Philippines*  
March 3 (Sun.)

- Diplomate (since 2012) and Fellow (since 2014), Philippine Society of Nuclear Medicine  
- Fellow (since 2017), Asian Nuclear Medicine Board  
- Certified Clinical Densitometrist  
- Pioneer of Theranostics in the Philippines after having trained at Zentralklinik Bad Berka, Germany from July to September 2016  
- Board Director and Head of Residency Training Council (since 2017), Philippine Society of Nuclear Medicine  
- Editor-in-Chief (since 2015), Philippine Journal of Nuclear Medicine  
- Residency Training Officer (since 2018) of the Department of Nuclear Medicine and PET Center, St. Luke’s Medical Center – Global City  
- Nuclear Medicine Consultant at St. Luke’s Medical Center – Global City and Quezon City (since 2012) and National Kidney and Transplant Institute (since 2018), among other affiliations

**Humayun Bashir**  
*Shaukat Khanum Memorial Cancer Hospital & Research Centre, Pakistan*  
March 3 (Sun.)

* Designation: Consultant & Head of Nuclear Medicine Department  
* Institute/Organization: Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, PAKISTAN

Nuclear medicine physician with 20 years of experience in the specialty acquired in Pakistan, United Kingdom and Saudi Arabia. Special interest in hybrid scintigraphy and theranostics. Has authored over 25 indexed publications with over a hundred citations.  
- Fellow of the College of Physicians and Surgeons Pakistan (Pk)  
- Fellow of the Royal of College Physicians of Edinburgh(UK)  
- Fellow of the Royal of College Physicians London (UK)  
- Fellow of the European Board of Nuclear Medicine(EU)  
- Diplomate of the Certification Board of Nuclear Cardiology:2006-16 (USA)  
Henri Becquerel Fellowship in Pediatric Nuclear Medicine from UK Member Board of Directors of the Asia Oceanic Federation of Nuclear Medicine and Biology (AOFNMB)  
Immediate past president of the Pakistan Society of Nuclear Medicine (2015-17)  
Chairman for the 18th Shaukat Khanum Cancer Symposium (November 1-3, 2019)
OVERVIEW
Posters will be displayed in the lobby of Lotus Hall (3F) from March 1 (Fri.) to 3 (Sun). All poster presenters are encouraged to be at their poster panels for discussion with participants during the poster Q&A time.

Install
March 1 (Fri.) -11:00
Poster Q&A
March 1 (Fri.) 13:00-14:00 (PP-Odd No.)
March 2 (Sat.) 14:00-14:30 (PP-Even No.)
Dismantle
March 3 (Sun.) 10:00-

Poster (Panel) Code Topic
PP001 - PP063 Clinical
PP064 - PP097 Chemistry and Pharmacy
PP098 - PP108 Physics and Dosimetry
PP109 - PP136 Others

PP001 - PP063 CLINICAL
PP001 MIBG THERAPY FOR RELAPSED LARGE PHEOCHROMOCYTOMA POST DEBULKING SURGERY AND CHEMOEMBOLIZATION: A CASE REPORT AND EARLY EXPERIENCE OF KUALA LUMPUR GENERAL HOSPITAL
Ahmad Zaid Zanial* and Siti Zarina Amir Hassan
Nuclear Medicine Department, Kuala Lumpur General Hospital, Malaysia

PP002 THE NEW EXPERIENCE OF RSHS USING I-131 MIBG IN MANAGEMENT OF LATE STAGE OF NEUROBLASTOMA
Aleksander*, Basuki Hidayat†, Hendra Budiawan†, Budi Darmawan†, Erwin Affandi Soeria†, Achmad Hussein S. Kartamihardja†, Agus Anjanto† and Adang Gunawan‡
1Nuclear Medicine and Molecular Imaging, Universitas Padjadjaran / Hasan Sadikin General Hospital, Indonesia; 2 Center for Radiisotope and Radiopharmaceuticals Technology, National Nuclear Energy Agency Republik, Indonesia

PP003 COMPLETE RESPONSE OF RADIOACTIVE IODINE THERAPY IN AN UNUSUAL CASE OF HYPERFUNCTIONING METASTATIC THYROID CANCER: A CASE REPORT
Alvita Dewi Siswoyo, Johan S Masjhur*
Nuclear Medicine, Division of Radiology, Department Cipto Mangunkusumo, National General Hospital, Jakarta, Indonesia

PP004 IS TC-99M ETHAMBUTOL (EMB) SCINTIGRAPHY ABLE TO IDENTIFY UNKNOWN LESIONS OF PATIENTS WITH SUSPECTED TUBERCULOSIS (TB)?
Andreas Lim*, Basuki Hidayat, Hendra Budiawan, Rd. Erwin Affandi, Budi Darmawan and Achmad Hussein Kartamihardja*
Nuclear Medicine and Molecular Imaging, Dr. Hasan Sadikin General Hospital Bandung / Universitas Padjadjaran Bandung, Indonesia

PP005 68 GA PENTIXAFOR PET/CT IMAGING TARGETING CXCR4 CHEMOKINE RECEPTORS: FIRST ASIAN EXPERIENCE IN LUNG CARCINOMA
Ankit Watts†, Baljinder Singh†, Ninjit Dhanota†, Mehak Vohra†, Harmandeep Singh†, Rajender Kumar†, Amanjit Bal†, Rakesh Kapoor†, Sunil Arora*, Hans Wester†, Bhagwant Mittal† and Digamber Behra†
1Dept of Nuclear Medicine & PET, PGIMER, Chandigarh, India; 2Department of Immunopathology, PGIMER, Chandigarh, India; 3Dept of Histopathology, PGIMER, Chandigarh, India; 4Dept of Radiation Therapy, PGIMER, Chandigarh, India; 5Pharmaceutical Radiochemistry, Technical University of Munich, Germany; 6Dept of Pulmonary Medicine, PGIMER, Chandigarh, India
PP006 IODINE-REFRACTORY THYROID CANCER: A REVIEW OF 9 CASES
Ayu Dewi* and Yustia Jelani
Radiodiagnostic, Dharmais Cancer Hospital, Indonesia

PP007 PROSPECTIVE STUDY OF MYELOSUPPRESSION EFFECT ON PALLIATIVE BONE PAIN THERAPY WITH SAMARIUM-153 EDTMP: A PRELIMINARY STUDY
Bangbang Aryanto*
Nuclear Medicine, Hasan Sadikin Hospital, Indonesia

PP008 RA-223 THERAPY FOR BONY METASTASES IN CASTRATION-RESISTANT PROSTATE CANCER: FIRST EXPERIENCE IN SIRIRAJ HOSPITAL
Benjapa Khiewvan1, Pawana Pusuvan, Ajalaya Teyateeti, Pachee Chaudakshethrit and Sunanta Chiewvit
Radiology, The Faculty of Medicine Siriraj Hospital, Thailand

PP009 PREDICTION OF SILENT BRAIN METASTASIS IN PATIENTS WITH T1 AND T2 LUNG ADENOCARCINOMA ON F-18 FDG PET/CT: IS THERE AN ADDITIVE ROLE TO GUIDE FURTHER BRAIN EVALUATION IN PATIENTS WITH EARLY T-STAGE ON CT
Gi Jeong Cheon* and Bolormaa Ganbaatar*
1 Nuclear Medicine, Seoul National University Hospital, Korea, 2 Nuclear Medicine, First State Central of Hospital, Mongolia

PP010 STUDY ON THE RELATIONSHIP BETWEEN THE FDG-PET/CT MAXSUV OF PRIMARY TUMOR AND EGFR MUTATION STATUS IN LUNG ADENOCARCINOMA
Bui Cong1, Pham Phuong2* and Pham Thai1
1 Nuclear Medicine Department, Ho Nai Medical University, Vietnam, 2 Nuclear Medicine and Oncology Center, Bach Mai Hospital, Vietnam

PP011 PROGNOSTIC IMPLICATION OF CHANGES IN DYNAMIC RISK STRATIFICATION OF 2015 ATA GUIDELINES
Chae Moon Hong, Ju Hye Jeong, Seung Hyun Son, Chang-Hee Lee, Sang-Woo Lee, Shin Young Jeong, Jaetae Lee and Byeong-Cheol Ahn*
Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Korea

PP012 ROLE OF PET/CT: EMERGING THERANOSTIC APPROACH IN MANAGEMENT OF DIFFERENTIATED THYROID CANCER IN MYANMAR
Chaw Hsu Win*, Kyin Myint1 and War War Wann Maung1
1 Department of Nuclear Medicine, Yangon General Hospital, Ministry of Health and Sports, Myanmar, 2 Myanmar Nuclear Medicine Society, Myanmar

PP013 TREATMENT OF PREDOMINANTLY LYMPH NODE METASTATIC PROSTATE CANCER WITH 177LU-PSMA RADIOLIGAND THERAPY
Finn Von Eyben*, Danielle Meyrick1, Nat Lenzo1 and Avril Singh1
1 Research, Centre of Tobacco Control Research, Denmark, 2 Oncology - Theranostics, GenesisCare, Australia, 3 Theranostics Centre for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Germany

PP014 FOLLOW UP OF REFRACTORY TO RADIOIOIDINE DIFFERENTIATED THYROID CARCINOMA PATIENTS AT TERTIARY INSTITUTE
Fatima Begum1, Jasmin Ferdous1, Urmas Islam1, Rahima Perveen1, Farhana Haque1, Afm Kamal Uddin1, Mohammad Abdus Sattar* and Nurun Nahar1
1 National Institute of Nuclear Medicine & Allied Sciences (NINMAS), Bangladesh Atomic Energy Commission, Bangladesh, 2 Department of Radiation Oncology, National Institute of Ear, Nose & Throat, Bangladesh, 3 Department of Otolaryngology-Head & Neck Surgery, Bangabandhu Sheikh Mujib Medical University, Bangladesh
POSTER

PP015 CORRELATION BETWEEN SERUM TG-ON AND PERSISTENT DISEASE IN PATIENTS WITH WELL DIFFERENTIATED THYROID CARCINOMA

Budi Darmawan¹, Johan Masjhur² and Febby Hutomo³
¹ Nuclear Medicine, RS Hasan Sadikin Bandung, Indonesia, ² Nuclear Medicine, RS Hasan Sadikin, Indonesia, ³ Nuclear Medicine, MRCC Siloam Hospital, Indonesia

PP016 DEEP LEARNING ONLY BY NORMAL BRAIN PET IDENTIFY UNHERALDED BRAINANOMALIES

Hongyoon Choi, Seunggyun Ha, Hyejin Kang, Hyekyoung Lee and Dong Soo Lee
Department of Nuclear Medicine, Seoul National University Hospital, Korea

PP017 LOW VERSUS HIGH DOSE RADIOIODINE REMNANT ABLATION FOR INTERMEDIATE RISK DIFFERENTIATED THYROID CARCINOMA: A META-ANALYSIS

Ivana Mulyanto¹
Nuclear Medicine Department of MRCC Siloam Semanggi, ISNM, Indonesia

PP018 LUNG METASTASES WHEN LEFT UNTREATED MAY LEAD TO HYPERTHYROIDISM: A CASE REPORT

Ivana Mulyanto¹
Nuclear Medicine Department of MRCC Siloam Semanggi, ISNM, Indonesia

PP019 18F-FDG PET/CT OF NEUROLYMPHOMATOSIS WITH A BACKGROUND OF OVARIAN CARCINOMA

Anastasia Saveleva¹ and Jamilla Gomez²
¹ PET/CT Center, Federal Siberian Research Clinical Center, Russia, ² Nuclear Medicine, National Kidney and Transplant Institute, Philippines

PP020 RADIOIODINE TREATED DIFFERENTIATED THYROID CANCER PATIENTS WITH LUNG METASTASES: FOLLOW UP ANALYSIS FOR MORE THAN 10 YRS

Jasmin Ferdous¹, Fatima Begum¹, Umaras Islam¹, Rahima Perveen¹, Sharmin Quddus¹, Zeenat Jabin¹, Farhana Haque¹, Abdus Shakur Khan² and Nurun Nahar³
¹ Thyroid Division, National Institute of Nuclear Medicine & Allied Science (NINMAS), Bangladesh Atomic Energy Commission, Bangladesh, ² Pulmonology, National Institute of chest disease & hospital, Bangladesh, ³ Director, National Institute of Nuclear Medicine & Allied Science (NINMAS), Bangladesh Atomic Energy Commission, Bangladesh

PP021 FIRST-IN-HUMAN STUDY OF A NOVEL SOMATOSTATIN RECEPTOR ANTAGONIST 68GA-NODAGA-LM3 FOR MOLECULAR IMAGING OF PARAGANGLIOMA PATIENTS

Jingjing Zhang¹, Aviral Singh, Harshad Kulkarni, Christiane Schuchardt and Richard Baum
THERANOSTICS Center for Molecular Radiotherapy & Precision Oncology, Zentralklinik Bad Berka, Germany

PP022 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) IN PATIENTS WITH GRADE 3 NEUROENDOCRINE NEOPLASMS (NEN)

Jingjing Zhang¹, Harshad Kulkarni, Aviral Singh, Karin Niepsch, Dirk Muller and Richard Baum
THERANOSTICS Center for Molecular Radiotherapy & Precision Oncology, Zentralklinik Bad Berka, Germany

PP023 177Lu-PSMA-617 RADIOLIGATION THERAPY IN MCRPC PATIENTS WITH A SINGLE FUNCTIONING KIDNEY

Jingjing Zhang¹, Harshad Kulkarni, Aviral Singh, Christiane Schuchardt, Karin Niepsch, Thomas Langbein and Richard Baum
THERANOSTICS Center for Molecular Radiotherapy & Precision Oncology, Zentralklinik Bad Berka, Germany

PP024 PROGNOSTIC VALUE OF 18F-FDG PET/CT IN A LARGE COHORT OF 495 PATIENTS WITH ADVANCED NEUROENDOCRINE NEOPLASMS (NEN) TREATED WITH PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)

Jingjing Zhang¹, Harshad Kulkarni, Aviral Singh, Karin Niepsch and Richard Baum
THERANOSTICS Center for Molecular Radiotherapy & Precision Oncology, Zentralklinik Bad Berka, Germany
POSTER

PP025  LONG-TERM NEPHROTOXICITY AFTER PRRT: MYTH OR REALITY?
Jingjing Zhang, Harshad Kulkarni, Karin Niepsch, Aviral Singh, Christiane Schuchardt and Richard Baum
THERANOSTICS Center for Molecular Radiotherapy & Precision Oncology, Zentralklinik Bad Berka, Germany

PP026  PREGNANCY AND DELIVERY AFTER PRRT WITHOUT SEQUELAE
Jingjing Zhang, Harshad Kulkarni, Coline Lehmann, Aviral Singh and Richard Baum
THERANOSTICS Center for Molecular Radiotherapy & Precision Oncology, Zentralklinik Bad Berka, Germany

PP027  THE RELATIONSHIP AND PROGNOSIS VALUE OF METABOLIC AND GENOMIC HETEROGENEITY BASED ON INTEGRATIVE ANALYSIS OF FDG-PET AND GENOMIC DATA IN HEAD AND NECK SQUAMOUS CELL CARCINOMA
Jinyeong Choi, Jung-An Kim, Chiwoo Oh, Hyung-Jun Im and Hongyoon Choi
1 Biomedical Radiation Sciences, Department of Transdisciplinary Studies, Seoul National University, Korea, 2 Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea

PP028  XI-CHROMOSOME REACTIVATION AS A THERAPEUTIC APPROACH FOR X-LINKED CARDIOMYOPATHIES
K M Ng and HF TSE
Medicine, The University of Hong Kong, Hong Kong

PP029  THERANOSTIC APPROACH USING FBPA-PET IN BORON NEUTRON CAPTURE THERAPY
Ko-Han Lin, Yi-Wei Chen, Ling-Wei Wang, Fong-In Chou, Chi-Wei Chang and Wen-Sheng Huang
1 Department of Nuclear Medicine, Taipei Veterans General Hospital, Taiwan, 2 Division of Radiotherapy, Department of Oncology Medicine, Taipei Veterans General Hospital, Taiwan, 3 Nuclear Science and Technology Development Center, National Tsing-Hua University, Taiwan

PP030  ROLE OF PET/CT: EMERGING THERANOSTIC APPROACH IN MANAGEMENT OF DIFFERENTIATED THYROID CANCER IN MYANMAR
Chaw Hsu Win, Kyin Myint and War War Wann Maung
1 Department of Nuclear Medicine, Yangon General Hospital, Ministry of Health and Sports, Myanmar, 2 Myanmar Nuclear Medicine Society, Myanmar Nuclear Medicine Society, Myanmar

PP031  177LU-DKFZ-PSMA-617 THERAPY IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER: SAFETY, EFFICACY AND QUALITY OF LIFE ASSESSMENT
Madhav Yadav, Sanjana Ballal and Chandrasekar Bal
Nuclear Medicine, All India Institute of Medical Sciences, India

PP032  IMPACT OF I-131 SPECT/CT ON AMERICAN THYROID ASSOCIATION (ATA) RISK STRATIFICATION IN DIFFERENTIATED THYROID CANCER
Mairah Raza*, Saima Riaz, Aamna Hassan and Humayun Bashir
Nuclear Medicine, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Pakistan

PP033  SAFETY PROFILE AND THERAPEUTIC EFFICACY OF ONE CYCLE OF [177LU] PSMA IN END STAGE METASTATIC CASTRATION RESISTANT PROSTATE CANCER PATIENTS WITH LOW PERFORMANCE STATUS
Mansi Gupta, Partha Choudhury, Sudhir Rawal, Harish Goel, Vineet Talwar, Kumar Dutta, Amitabh Singh and Anita Gupta
1 Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, 2 Uro - Gynaec Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India, 3 Amity Centre for Radiation Biology, Amity University, Noida, Uttar Pradesh India, India, 4 Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Delhi, India, 5 Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India
PP034  EFFECTS OF THYROXINE WITHDRAWAL IN PATIENTS WITH DIFFERENTIATED THYROID CANCER
Md Sayedur Miah1*, Md Islam1, Md Pervej1 and Kanij Rudba2
1 Institute of Nuclear Medicine & Allied Sciences, Dhaka, Bangladesh Atomic Energy Commission, Bangladesh, 2 Institute of Nuclear Medicine & Allied Sciences, Camilla, Bangladesh Atomic Energy Commission, Bangladesh

PP035  ASSESSMENT OF BONE METASTASES IN PATIENTS WITH PROSTATE CANCER? A COMPARISON BETWEEN 99MTC-MDP BONE SCINTIGRAPHY AND 177Lu-CC 34 PSMA PRELIMINARY STUDY
Megawatti Setiabudi1*, Ayu Dewi2*, Hendra Budiawan3, Achmad Kartamihardja4, Nur Hidayanti5, Elly Rosilawati6 and Rini Shintawati1
1 Nuclear Medicine and Molecular Imaging, RSIP Dokter Hasan Sadikin, Indonesia, 2 Nuclear Medicine and Molecular Imaging, Dharmais National Cancer Hospital, Indonesia

PP036  F18-FDG PET PARAMETERS REFLECTING MICROSATELLITE INSTABILITY STATUS AND IMMUNE MICROENVIRONMENT IN STAGE II AND III PROXIMAL COLON CANCER
Minseok Suh1*, Jin Chul Paeng2, Seunggyun Ha and Gi Jeong Cheon
Department of Nuclear Medicine, Seoul National University Hospital, Korea

PP037  THE INCIDENCE OF REPEATED THERAPY IN HYPERTHYROID PATIENTS THAT RECEIVED INITIAL NAI-131 EMPIRICALLY AT DEPARTMENT OF NUCLEAR MEDICINE AND MOLECULAR IMAGING DR. HASAN SADIKIN GENERAL HOSPITAL BANDUNG
Muhammad Fahmi1*, Basuki Hidayati, Hendra Budiawan, Raden Erwin Soerianto, Budi Darmawan and Ahmad Hussein Kartamihardja
Nuclear Medicine, Hasan Sadikin Hospital Bandung, Indonesia

PP038  LU-177 PRRT IN PATIENTS OF NEUROENDOCRINE TUMORS AT INMOL; 10 MONTHS’ EXPERIENCE AT FIRST THERANOSTICS CENTER OF PAKISTAN
Muhammad Numair Younis1*, Abubaker Shahid2, Irfanullah Khan3, Misbah Masood3, Ahmad Qureshy4 and Ismat Fatima5
1 Nuclear Medicine, INMOL Cancer Hospital, Lahore, Pakistan, 2 Clinical Oncology, INMOL Cancer Hospital, Pakistan, 3 Radiopharmacy, INMOL Cancer Hospital, Pakistan, 4 Clinical Pharmacy, INMOL Cancer Hospital, Pakistan

PP039  EFFICACY OF RECOMBINANT HUMAN THYROID STIMULATING HORMONE (RHTSH) ON WHOLE BODY IODINE CLEARANCE IN DIFFERENTIATED THYROID CANCER
Noradina Mat Nawi1*, Mohd Fazrin Mohd Rohani1, Nurul Shahirah Ahmad2, Reduan Abdullah2, Wan Fatiah Wan Sohaimi1 and Wan Mohd Nazlee Wan Zainon1
1 Nuclear Medicine Department, School of Medical Sciences, Universiti Sains Malaysia, Malaysia, 2 Medical Radiation Programme, School of Health Sciences, Universiti Sains Malaysia, Malaysia, 3 Family Medicine Department, School of Dental Sciences, Universiti Sains Malaysia, Malaysia

PP040  ULTRASOUNDS OF FETAL UROGENITAL CONGENITAL ABNORMALITIES
Nyamgerel Batdelger1* and Erdembileg Tsevegmid1
1 Nuclear Medicine Department, The First Central Hospital of Mongolia, Mongolia, 1 Head of Radiology Department of Mongolia, MNUMS (Mongolian National University of Medical Science), Mongolia

PP041  18F-PSMA-HBED-CC AND 177Lu-PSMA-617 A POTENTIAL THERAGNOSTIC TANDEM FOR PROSTATE CANCER?
Omar Alonso1*, Gerardo Dos Santos1, Juan Hermida1, Monica Rodriguez1, Enzo Silvera2, Eugenia De Marco1, Javier Giglio1, Victoria Trindade1, Laura Vera3, Eduardo Savi1, Henia Balter1 and Henry Hengler1
1 Uruguayan Center of Molecular Imaging (CUDIM), Uruguay, 2 Nuclear Medicine and Molecular Imaging Center, Hospital de Clinicas, Universidad de la Republica, Uruguay, 1 Oncology Department, National Cancer Institute (INCA), Uruguay
PP042 THE ESTABLISHMENT OF GALLIUM-68 AND LUTETIUM-177 THERANOSTICS IN THE PHILIPPINES
Patricia Bautista*
Nuclear Medicine and PET Center, St. Luke's Medical Center, Philippines

PP043 ENDEAVORS TO IMPLEMENT THERANOSTICS IN VIETNAM
Mai Khoa¹, Pham Phuong Tran Ha and Pham Thai
The Nuclear Medicine and Oncology Center, Bach Mai Hospital, Vietnam

PP044 PROGNOSTIC VALUE OF TUMOR NECROSIS AT FDG PET IN NON-SMALL CELL LUNG CANCER PATIENTS
Pupree Mutsuddy¹,², Suh Minseok¹, Seunggyun Ha¹, Qaid Ahmed Shagera¹ and Jin Chul Paeng¹
¹ National Institute of Nuclear Medicine and Allied Sciences, Bangladesh; ² Nuclear Medicine, Seoul National University, Korea

PP045 METASTASIS PATTERN IN PROSTATE CANCER BASED ON BONE SCINTIGRAPHY EXAMINATION
Puspa Handayani¹, Basuki Hidayat, Hendra Budiawan, Budi Darmawan, Rd. Erwin Affandi, Achmad Hussein Kartamihardja and Johan Masjhur
Nuclear Medicine and Molecular Imaging, Dr. Hasan Sadikin General Hospital Bandung / Universitas Padjadjaran Bandung, Indonesia

PP046 AN ADDITIVE PROGNOSTIC VALUE OF METABOLIC TUMOR VOLUME ON BASELINE F-18 FDG-PET/CT TO NCCN-IPI IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: FURTHER STRATIFICATION OF THE HIGH-RISK GROUP IN NCCN-IPI
Qaid Ahmed Shagera¹, Gi Jeong Cheon¹*, Youngil Koh², Min Young Yoo³, Keon Wook Kang¹, Dong Soo Lee¹, E. Edmund Kim⁴, Sung-Soi Yoon¹ and June Key Chung³
¹ Department of Nuclear Medicine, Seoul National University, College of Medicine, Seoul, Korea; ² Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; ³ Department of Nuclear Medicine, Chungbuk National University Hospital, Cheongju, Korea; ⁴ Department of Nuclear Medicine, Department of Radiological Sciences, University of California, Irvine, CA, USA

PP047 THYROID FUNCTION EVALUATION IN NEWBORN OF MOTHERS WITH DIFFERENTIATED THYROID CARCINOMA AFTER RADIOIODINE TREATMENT AT TERTIARY HOSPITAL
Rahima Perveen¹, Fatiema Begum, Jasmin Ferdous, Umaras Islam, Zeenat Jabin, Sharmin Quddus, Farhana Haque and Nurun Nahar
Thyroid Division, National Institute of Nuclear Medicine and Allied Sciences (NINMAS), Bangladesh Atomic Energy Commission, Bangladesh

PP048 PRRT AS PART OF A TREATMENT PLAN IN GASTROENTEROPANCREATIC-NET IN CHILE: RESULTS OF OUR LOCAL EXPERIENCE
Horacio Amaral¹*, Rossana Pruzzo¹, Rene Fernandez², Cristian Soza-Ried³, Vasko Kramer² and Ana Hurtado De Mendoza³
¹ Nuclear Medicine, PositronMed, Chile; ² Nuclear Medicine, PositronPharma, Chile

PP049 PRRT RETREATMENTS: RENAL FUNCTION EVALUATION
Riccardo Laudicella¹*, Fabio Minutili, Antonio Vento, Alessio Comis, Rossella Filice, Helena Lanzafame, Barbara Catalfarno, Cristina Mantaro, Benetta Pagano and Sergio Baldari
Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Italy

PP050 COMPLETE RESPONSE IN A PANCREATIC NEN WITH LIVER METASTASIS AFTER PRRT IN ASSOCIATION WITH LANREOTIDE AUTOGEL/DEPOT: DESIGN OF THE PRELUDE STUDY
Riccardo Laudicella¹*, Fabio Minutili², Rossella Filice³, Lucia Baratto³, Antonio Vento³, Salvatore Pignata³, Alessio Comis³, Francesco Panasiti³, Benedetta Pagano³ and Sergio Baldari³
¹ Nuclear Medicine - Italian Resident Program, University Hospital G.Martino, Messina, Italy; ² Unit of Nuclear Medicine, Department of Biomedical and Dental Sciences and Morphological Imaging, University of Messina, Messina, Italy; ³ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA, USA
POSTER

PP051 PROGNOSTIC VALIDITY OF DUAL TRACER PET/CT IN THE PRRT ENROLLMENT OF GEP-NET PATIENTS
Salvatore Pignata1, Alfredo Campanpi, Riccardo Laudicella, Flavia Quattrrocchi, Alessio Comis, Rossella Filice, Antonio Vento, Barbara Catafago, Francesco Panasiti, Fabio Minutoli, Davide Cardile, Benedetta Pagano and Sergio Baldari
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Nuclear Medicine Unit, University of Messina, Italy

PP052 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY AND SOMATOSTATIN 'COLD' ANALOGUES THERAPY IN THE TREATMENT OF GEP-NET PATIENTS: OUR CENTER EXPERIENCE
Salvatore Pignata1, Alfredo Campanpi, Riccardo Laudicella, Flavia Quattrrocchi, Alessio Comis, Antonio Vento, Helena Lanzafame, Cristina Mantaro, Ernesto Amato, Benedetta Pagano, Davide Cardile, Fabio Minutoli and Sergio Baldari
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Nuclear Medicine Unit, University of Messina, Italy

PP053 GA-68 DOTATATE PET/CT EVALUATION FOR PRRT IN ADULT NEUROBLASTOMA
Aaron Tong1, Sean Yan1, Sueping Thang1, Kelvin Loke1, Shui Yen Soh2, Amos Loh3 and Mohamad Farid4
1 Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore, 2 Pediatric Haematology/Oncology Service, KK Women’s and Children’s Hospital, Singapore, 3 Paediatric Surgery, KK Women’s and Children’s Hospital, Singapore, 4 Medical Oncology, National Cancer Centre Singapore, Singapore

PP054 THE QUANTITATIVE ANALYSIS OF POST- SELECTIVE INTERNAL RADIATION THERAPY (SIRT) 90Y MICROSPHERES PET/CT IN HEPATOCELLULAR CARCINOMA IN COMPARISON WITH 99MTC-LABELLED MACROAGGREGATED ALBUMIN (MAA) PLANAR
Kien Nguyen1, Son Mai and Ha Ngoc
Nuclear Medicine, Tran Hung Dao Hospital, Vietnam

PP055 ACCURACY OF CKD-EPI EQUATION IN CORRELATION WITH 99MTC DTPA RENOGRAM TO ESTIMATE GFR OF CHRONIC KIDNEY DISEASE AT NORTH OKKALAPA GENERAL HOSPITAL, MYANMAR
Su Thet Oo1*, Nway Nway Hla Phone2, Kyin Myint3 and Khin Pa Pa Myo3
1 Department of Nuclear Medicine, North Okkalapa General Hospital, Ministry of Health and Sports, Yangon, Myanmar, 2 Department of Medicine, Ministry of Health and Sports, Yangon, Myanmar, 3 Department of Nuclear Medicine, President of Myanmar Nuclear Medicine Society (Director, Perfect Molecular Imaging and Therapy Center) Yangon, Myanmar

PP056 IS SINGLE LOW-PROFILE VISUALIZED INTRALUMINAL SUPPORT (LVIS) ASSISTED COILING OF WIDE-NECKED RUPTURED MULTIPLE INTRACRANIAL ANEURYSMS IN ONE-STAGE FEASIBLE?
Tangming Peng and Wenhua Zheng
Faculty of Health Science, University of Macau, China

PP057 INCIDENTAL FINDING IN BONE SCAN
Tin Maung Thein* and Win Maung
Molecular Imaging Center, Perfect Myanmar Molecular Imaging and Therapy Center, Myanmar

PP058 ANALYSIS UPTAKE 177 LU-CC 34 PSMA IN SALIVARY GLANDS OF PROSTATE CANCER PATIENTS
Tri Pera Sucianti1*, Ayu Dewi1, Hendra Budiaawan2, Nur Rahmah Hidayati3, N. Elli Rosilawati4, Rini Shintawati5, Basuki Hidayat5 and Achmad Hussein Kartamihardja1
1 Nuclear Medicine and Molecular Imaging, Dr. Hasan Sadikin General Hospital Bandung / Universitas Padjadjaran Bandung, Indonesia, 2 Nuclear Medicine and Molecular Imaging, Dharmais Cancer Hospital, Indonesia, 3 Center for Technology of Radiation Safety and Metrology, BATAN, Indonesia

PP059 XEROSTOMIA ASSESSMENT WITH XEROSTOMIA QUESTIONNAIRE IN PATIENTS WITH PROSTATE CANCER UNDERWENT DIAGNOSTIC PROCEDURES USING Lu177-CC34
Wulan Apriliani1*, Ayu Dewi1, Hendra Budiaawan1, Nur Rahmah Hidayati1, N. Elli Rosilawati1, Rini Shintawati1, Basuki Hidayat1 and Achmad Hussein Kartamihardja1
1 Nuclear Medicine and Molecular Imaging Department, Dr. Hasan Sadikin General Hospital, Universitas Padjadjaran, Indonesia, 2 Nuclear Medicine and Molecular Imaging Department, Dharmais Cancer Hospital, Indonesia, 3 Center for Technology of Radiation Safety and Metrology, BATAN, Indonesia
POSTER

PP060 INITIAL EXPERIENCE ON THE CLINICAL SAFETY AND TREATMENT EFFICACY OF PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT): LOCAL EXPERIENCE IN A SINGLE CENTER
Yan Ho Hui*, Ting Kun Au Yong and Boom Ting Kung
Nuclear Medicine, Queen Elizabeth Hospital, Hong Kong

PP061 CHEMOKINE RECEPTOR CXC4-TARGETED PET/CT WITH 68GA-PENTIXAFOR SHOWS SUPERIORITY TO 18F-FDG IN EVALUATION OF MULTIPLE MYELOMA
Yaping Luo1*, Qingqiu Pan1, Xinxin Cao2 and Jian Li2
1 Nuclear Medicine, Peking Union Medical College Hospital, China; 2 Hematology, Peking Union Medical College Hospital, China

PP062 THERAPEUTICAL RESPONSE EVALUATION ON HYPERTHYROIDISM USING I-131 FIXED DOSE
Yulia Kurniawati1 and Ahs Kartamihardja2
1 Nuclear Medicine of Medical Faculty Universitas Andalas, Indonesia Society of Nuclear Medicine, Indonesia; 2 Nuclear Medicine of Medical Faculty Universitas Padjadjaran, Indonesia Society of Nuclear Medicine, Indonesia

PP063 DISCREPANCY BETWEEN EXERCISE ECG (TREADMILL) WITH MYOCARDIAL PERFUSION IMAGING IN PATIENT WITH SUSPECT CAD
Zulhendri Syauki1, Ahs Kartamihardja, Rd. Erwin Soerjadi and Hendra Budiawan
Department of Nuclear Medicine and Molecular Imaging, Faculty of Medicine Padjadjaran / Dr. Hasan Sadikin General Hospital, Indonesia

PP064 - PP097 CHEMISTRY AND PHARMACY

PP064 CHARACTERIZATION UPTAKE AND CYTOTOXIC OF RADIOIODINE IN MCF-7 AND SKBR-3 BREAST CANCER CELL LINES
Aisyah Elliyanti1*, Veronica Susilo3, S. Setiyowati3, Martalena Ramli2, Johan Masjhu1 and Tri Achmad4
1 Medical Physics/Radiology, Faculty of Medicine Universitas Andalas, Indonesia Society of Nuclear Medicine, Indonesia; 2 Radiosotope and Radiopharmaceutical Technolog Center, National Nuclear Energy Agency, Kawasan Puspitek Serpong, Indonesia; 3 Department of Nuclear Medicine, Padjadjaran University, Bandung, Indonesia; 4 Department of Biochemistry, Padjadjaran University, Bandung, Indonesia

PP065 TARGETING OF SOMATOSTATIN RECEPTOR SUBTYPE-2 FOR FLUORESCENCE-GUIDED SURGERY
Servando Hernandez Vargas, Julie Yoss, Sukhen Ghosh, Jo Simien and Ali Azhdarinia*
McGovern Medical School, The University of Texas Health Science Center at Houston, USA

PP066 COMPARISON OF [18F]DMFB AND [18F]DMPY2 AS PET IMAGING AGENTS FOR MALIGNANT MELANOMA
Ayoung Pyo, Ye-Rim Jung, Seong Young Kwon, Dong-Yeon Kim* and Jung-Joon Min*
Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, Korea

PP067 RADIOLABELING OF A TA-MUC1 SPECIFIC MONOCLONAL ANTIBODY AND ITS CORRESPONDING SINGLE CHAIN FRAGMENT WITH 89ZR, 44SC AND 177LU FOR BREAST CANCER THERANOSTICS
Benedikt Klasen1, Natascha Stergiou2, Euy Sung Moon1, Edgar Schmitt1 and Frank Roesch1*
1 Institute for Nuclear Chemistry, Johannes Gutenberg-University Mainz, Germany; 2 Institute for Immunology, University Medical Center Mainz, Germany

PP068 ESTABLISHING CENTRALISED MANUFACTURE OF NEXT GENERATION THERANOSTICS (CU-64/CU-67)
Colin Biggin1*, Kevin Kuan2, Prab Takhar2, Ellen Van Dam3 and Matthew Harris3
1 Clarity Pharmaceuticals, Clarity Pharmaceuticals, Australia; 2 MITR, SAHMRI/Clarity Pharmaceuticals, Australia; 3 MITR, SAHMRI, Australia
PP069 CYCLOTRON PRODUCED GA-68 AND THEIR POST-PROCESSING USING SOLID TARGETS - INITIAL RESULTS
Dirk Mueller1, Mirko Sclitter1, Stefan Sentfleber1 and Michael Proehl1
1 Radiopharmacy, Zentralklinik Bad Berka GmbH, Germany; 2 Klinik fuer Molekulare Radiotherapie / Zentrum fuer Molekulare Bildgebung, Zentralklinik Bad Berka GmbH, Germany

PP070 TARGETED ALPHA-PARTICLE THERAPEUTICS - ADAPTATION OF CLINICAL ROUTINELY PRODUCED AC-225-LABELED RADIOPHARMACEUTICALS
Dirk Mueller1, Michael Proehl1, Christiane Schuchardt2, Harshad Kulkarni1, Jingjing Zhang2, Aviral Singh2 and Richard Baum3
1 Radiopharmacy, Zentralklinik Bad Berka GmbH, Germany; 2 Theranostic Center for Molecular Radiotherapy, Zentralklinik Bad Berka GmbH, Germany

PP071 ENHANCING SST2-TARGETED ALPHA-PARTICLE THERAPY FOR NEUROENDOCRINE TUMORS WITH EVEROLIMUS AND HISTONE DEACETYLASE INHIBITORS
Dongyoul Lee1*, Mengshi Li2, Dijie Liu3, Somya Kapoor4, Joshua Prindle5, Addelynn Smith6 and Michael Schultz7
1 Human Toxicology, University of Iowa, USA; 2 Department of Radiology, University of Iowa, USA; 3 Stead Family Department of Pediatrics, University of Iowa, USA; 4 Free Radical and Radiation Biology, University of Iowa, USA; 5 Chemistry, University of Virginia, USA; 6 Biology, University of California, Berkeley, USA; 7 Human Toxicology, Stead Family Department of Pediatrics, Radiation Oncology, and Chemistry, University of Iowa, USA

PP072 SYNTHESIS AND PRELIMINARY EVALUATION OF A NOVEL FAP-INHIBITOR CONTAINING SQUARIC ACID COUPLED DOTA
Elisabeth Eppard1, Lukas Greifenstein1, Euy-Sung Moon1, Tilmann Grus1, Vasko Kramer2 and Frank Roesch1
1 Institute of Nuclear Chemistry, Johannes Gutenberg University, Germany; 2 Radiopharmacy, PositronPharma, Chile

PP073 DEVELOPMENT OF A NEW BIFUNCTIONAL PSMA LIGAND AS A THERANOSTIC FOR PROSTATE CANCER
Nicholas Zia1, Carleen Cullinane2, Jessica Van Zuylen3, Kelly Waldeck2, Gojko Buncic1, Peter Roselt1, Amos Hedt4, Ellen Van Dam5, Matthew Harris6, Michelle Parker7 and Paul Donnelly7
1 Department of Chemistry, The University of Melbourne, Australia; 2 Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Australia; 3 R&D, Clarity Pharmaceuticals, Australia

PP074 AAZTA.SQUARIC ACID AS A PROMISING CONJUGATE FOR RADIOLABELLING MONOCLONAL ANTIBODIES WITH LUTETIUM-177 UNDER MILD CONDITIONS
Euy-Sung Moon, Benedikt Klasein and Frank Roesch1
Institute of Nuclear Chemistry, Johannes Gutenberg University Mainz, Germany

PP075 SENSITIVE FLUORESCENCE DETECTION OF PEROXYNITRITE ENABLED BY A NANOHYBRID IN THE PROCESS OF INFLAMMATION
Hai-Hao Han and Xiao-Peng He1
School of Chemistry and Molecular Engineering, East China University of Science and Technology, China

PP076 IN VITRO EVALUATION OF NOVEL SQUARIC ACID COUPLED AAZTAS AND DATA CONJUGATED KUE TARGETING VECTORS
Hanane Lahnif1*, Lukas Greifenstein1, Tilmann Grus1, Marlies Weber1, Ralf Bergmann1, Stefanie Pektor1 and Frank Roesch1
1 Institute of Nuclear Chemistry, Johannes Gutenberg University Mainz, Germany; 2 Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany; 3 Clinic for Nuclear Medicine, University Medical Center Mainz, Germany

PP077 IN THE ASSESSMENT OF BIODISTRIBUTION AND METABOLISM FOR A-METHYLATION ON 18F-LABELED TRYPTOPHAN DERIVATIVE
Ho Young Kim, Ji Youn Lee, Sang Hun Lee, Mee Kyung Hong, Yun-Sang Lee, Dong Soo Lee, Keon Wook Kang and Jae Min Jeong1
Department of Nuclear Medicine, Seoul National University, Korea
PP078  CAPACITY BUILDING IN THERANOSTICS: INITIAL EXPERIENCE AT INMOL-LAHORE, BEING FIRST THERANOSTICS CENTER IN PAKISTAN
Irfan Ullah Khan1, Muhammad Numair2, Rizwana Zahoor1, Nouroze Gul1 and Abubaker Shahid3
1 Cyclotron and Allied Radiopharmaceutics, INMOL Cancer Hospital, New Campus Road, Lahore-54600, Pakistan; 2 Nuclear Medicine and PET-CT, Institute of Nuclear Medicine & Oncology (INMOL), New Campus Road, Lahore-54600, Pakistan; 3 Department of Radiation Oncology, Institute of Nuclear Medicine & Oncology (INMOL), New Campus Road, Lahore-54600, Pakistan

PP079  ANTI-TUMOR EFFECT OF CD206+ TAM-SPECIFIC DEPLETION WITH FINELY TUNED CLICKABLE LIPOSOMES-ENCAPSULATED CLODRONATE
Ji Yong Park1, Hyewon Chung2, Kyuwan Kim1, Minseok Suh4, Seung Hyeok Seok1 and Yun-Sang Lee2
1 Department of Nuclear Medicine, Department of Biomedical Sciences, Seoul National University, Korea; 2 Department of Microbiology and Immunology, Institute of Endemic Disease, Seoul National University, Korea; 3 Department of Nuclear Medicine, Seoul National University Hospital, Korea; 4 Graduate School of Convergence Science and Technology, Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Korea

PP080  EARLY DETECTION OF METASTASIS USING A CLICKABLE ALBUMIN NANO-PLATFORM BY TARGETING CD206+ TUMOR-ASSOCIATED MACROPHAGES
Ji Yong Park1, Hyewon Chung2, Kyuwan Kim1, Minseok Suh1, Seung Hyeok Seok2 and Yun-Sang Lee2
1 Department of Nuclear Medicine, Department of Biomedical Sciences, Seoul National University, Korea; 2 Department of Microbiology and Immunology, Institute of Endemic Disease, Seoul National University, Korea; 3 Department of Nuclear Medicine, Seoul National University Hospital, Korea; 4 Graduate School of Convergence Science and Technology, Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Korea

PP081  THE DEVELOPMENT OF EVANS BLUE AND MANNOSYLATED HUMAN SERUM ALBUMIN (MSA) CONJUGATE FOR SENTINEL LYMPH NODE MAPPING
Ji Youn Lee, Ho Young Kim, Hyeyeon Seo, Yun-Sang Lee and Jae Min Jeong*
Department of Nuclear Medicine, Seoul National University, Korea

PP082  SYNTHESIS OF 68Ga-HUMAN SERUM ALBUMIN NANOCOLLOID: A POTENTIAL LYMPHOSCINTIGRAPHY IMAGING AGENT
William Hsieh* and Karen Ho
Department Nuclear Medicine & Bone Densitometry, Royal Adelaide Hospital, South Australia, Australia

PP083  SIMPLE FUNCTIONALIZATION OF CHELATORS WITH SQUARE ACID USING THE EXAMPLE OF TRAM.PSMA
Lukas Greifenstein1, Nils Engelbogen1, Ralf Bergmann1 and Frank Rosch1
1 Institute of Nuclear Chemistry, Johannes Gutenberg-University Mainz, Germany; 2 Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Germany

PP084  PREPARING OPTIMAL HUMAN DOSES OF 68Ga-DOTA-TATE USING A KIT RADIOLABELING SOLUTION SUPPORTING PERSONALIZED RADIENDOTHERAPY
Thomas Ebenhan1, Cindy Davis2, Judith Wagener2, Biljana Marjanovic-Painter1, Jan Zeevaart1 and Mike Satherkorn1
1 Nuclear Medicine, University of Pretoria, South Africa; 2 Nuclear Medicine, Steve Biko Academic Hospital, South Africa

PP085  IGF-1 INDUCED MIGRATION AND INVASION OF UVEAL MELANOMA CELLS IS MEDIATED BY FOXO3A TRANSCRIPTION FACTOR
Mehd Farhan and Wen Hua Zheng
Faculty of Health Sciences, University of Macau, China
POINTER

PP086 DEVELOPMENT OF 99MTC-LABELED HUMAN SERUM ALBUMIN WITH PROLONGED CIRCULATION BY CHELATE-THEN CLICK APPROACH: A POTENTIAL BLOOD POOL IMAGING AGENT

Nadeem Ahmed Lodhi1, Ji Yong Park2, Kyuwan Kim2, Young Joo Kim2, Jae Hwan Shin2, Vinay Kumar Banka3, Yongkyung Kweon1, Jun-Sang Lee4, and Hyung-Jun Im5

1 Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea, 2 Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea, 3 Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea, 4 Nuclear Medicine, Seoul National University Hospital, Korea, 5 Department of Chemistry, Graduate School, Kyung Hee University, Korea, 6 Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea

PP087 EFFECT OF DIFFERENT HEATING DURATION ON 68GA-PSMA-HBED-CC RADIOLABELLING EFFICIENCY FOR PROSTATE CANCER IMAGING

Neneng Rosilawati1, Achmad Kartamihardja1, and Rayi Naura2

1 Nuclear Medicine General Hospital and Molecular Imaging Dr. Hasan Sadikin, Department of Nuclear Medicine and Molecular Imaging General Hospital Dr. Hasan Sadikin, Indonesia, 2 Faculty of Medicine Padjadjaran University, Indonesia

PP088 EFFECTIVELY ZR-89 INCORPORATED ON THE INSIDE OF IRON OXIDE NANOPARTICLES WITHOUT CHELATORS AND ITS IN-VIVO BEHAVIOR IN THE TUMOR XENOGRAFT MOUSE MODEL

Pyeong Seok Choi, Jun Young Lee, Chirag K. Vyas, Young Bae Kong, Eun Je Lee, Ho Seung Song, Seung Dae Yang, Min Goo Hur and Jeong Hoon Park

Radiation Instrumentation Research Division, Korea Atomic Energy Research Institute, Korea

PP089 PEGYLATED CRUSHED GOLD SHELL-RADIOLABELED CORE NANOBALLS FOR IN VIVO BIO IMAGING APPLICATION WITH DUAL POSITRON EMISSION TOMOGRAPHY AND CERENKOV LUMINESCENT IMAGING

Sang Bong Lee1, Jungwook Chin1, Sung Jin Cho1 and Yong Hyun Jeon1

1 New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Korea, 2 Laboratory Animal Center, Daegu-Gyeongbuk Medical Innovation Foundation, Korea

PP090 TSPO TARGETED THERANOSTICS FOR BLADDER CANCER IMAGING AND PHOTODYNAMIC THERAPY

Sang Hee Lee1,2, Jae Ho Jung2, In Ho Song2, Byung Chul Lee3,4,5 and Sang Eun Kim1,2,3

1 Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, 2 Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, 3 Center for Nanomolecular Imaging and Innovative Drug Development, Advanced Institutes of Convergence Technology, Suwon, Korea

PP091 BERBERINE PROTECTED RPE CELLS FROM H2O2 INDUCED OXIDATIVE STRESS VIA THE ACTIVATION OF THE AMPK PATHWAY

Shuai Li and Wenhua Zheng

Faculty of Health Sciences, University of Macau, China

PP092 IMAGING OF PD-L1 FOR IMMUNOTHERAPY MONITORING

Sven Stadlbauer1, Martin Schaefer, Ulrike Bauder-Wuest and Klaus Kopka

Radiopharmaceutical Chemistry, German Cancer Research Center, Germany

PP093 SYNTHESIS AND RADIOLABELING OF A NOVEL SQUARIC ACID COUPLED AAZTAS-KUE FOR THERANOSTICS OF PROSTATE CANCER

Tilmann Grus, Lukas Greifenstein, Jean-Philippin Sinnes and Frank Roesch

Institute for Nuclear Chemistry, Johannes Gutenberg-University Mainz, Germany
POSTER

PP094 SOLID LIPID NANOPARTICLES OF UMBELLIFERONE AND ITS ANTICANCER MOLECULAR MECHANISMS: COMPUTATIONAL APPROACHES VS INVIVO STUDY
Vikas Kumar*
Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, India

PP095 DEVELOPMENT OF RADIOLabeled EUROPiUM EMBEDDED NANOpiARiCLE FOR IN VIVO IMAGING AND GAMMA RAY INDUCED PHOTODYNAMiC THERAPY
Wooseung Lee, Miyoen Jeon, Jinyeong Choi, Chiuwoh Oh and Hyung-Jun Im
Department of Transdisciplinary Studies, Seoul National University, Korea

PP096 ACTIVATION OF AMPK PATHWAY IS INVOLVED IN THE PROTECTION OF METFORMIN ON PC12 CELLS AND HIPPOCAMPAL NEURONS AGAINST H2O2-INDUCED OXIDATIVE DAMAGE
Xia Zhao, Shuai Li, Jiankang Fang and Wenhua Zheng*
Faculty of Health Sciences, University of Macau, China

PP097 AQUAPORIN-4 DEFICIENCY REDUCES TGF-β1 IN MOUSE MIDBRAINS AND EXACERBATES PATHOLOGY IN EXPERIMENTAL PARKINSON’S DISEASE
Xue Xue1, Weizai Zhang2, Jifeng Zhu3, Xiaojun Chen1 and Chuan Su3*
1 Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, China; 2 Pathogen Biology and Immunology, Nanjing University of Traditional Chinese Medicine, China; 3 Pathogen Biology and Immunology, Nanjing Medical University, China

PP098 - PP108 PHYSICS AND DOSIMETRY

PP098 SERIAL LU-177 PSMA RADIOLIGAND THERAPY: VARIATION IN THE ABSORBED RADIATION DOSE AND PSA RESPONSE
Jingjing Zhang, Christiane Schuchardt1, Harshad Kulkarni, Aviral Singh, Thomas Langbein and Richard Baum
Theranostics Center for Molecular Radiotherapy, Zentralklinik Bad Berka GmbH, Germany

PP099 EXPERIMENTAL WORK UP AND VALIDATION OF 67Cu QUANTITATIVE SPECT
Kathy Willowson1, Matthew Harris2, Michelle Parker3, Colin Biggin4 and Dale Bailey1*
1 Department of Medical Physics, University of Sydney, Australia; 2 Clarity Pharmaceuticals, Australia; 3 Clarity Pharmaceuticals, Australia; 4 Department of Nuclear Medicine, Royal North Shore Hospital, Australia

PP100 ATTENUATION MAP GENERATION IN WHOLE-BODY PET/MRI BASED ON A DEEP NEURAL NETWORK APPLIED TO SIMULTANEOUSLY RECONSTRUCTED ACTIVITY AND ATTENUATION AND DIXON MRI
Donghwi Hwang1, Seungkwan Kang1, Kyeong Yun Kim2, Seongho Seo3 and Jae Sung Lee3*
1 Department of Nuclear Medicine, Seoul National University, Korea; 2 Department of Nuclear Medicine, Seoul National University, Brightonix Imaging, Korea; 3 Department of Neuroscience, Gachon University, Korea

PP101 A HAND-HELD ULTRA-LOW DOSE INTRAOPERATIVE X-RAY IMAGER: LARGE-ANIMAL IMAGING STUDY USING AGAR-BASED LUNG NODULE MODEL
Haewook Park1, Kook Nam Han2, Byeong Hyeon Choi2, Hyun Koo Kim2 and Jae Sung Lee2*
1 Department of Nuclear Medicine, Seoul National University Hospital, Korea; 2 Department of Thoracic and Cardiovascular Surgery, Korea University Guro Hospital, Korea

PP102 HIGHLY INTEGRATED FPGA-ONLY DATA ACQUISITION SYSTEM USING SINGLE-ENDED MEMORY INPUT RECEIVERS FOR TIME-OF-FLIGHT PET SCANNERS
Jun Yeon Won and Jae Sung Lee*
Department of Nuclear Medicine, Seoul National University Hospital, Korea
## POSTER

### PP103  RADIO-IODINE TREATMENT OF HYPERTHYROIDISM IN BANGLADESH: PATIENT SPECIFIC DOSIMETRY PLANNING

Lutfun Nisa*, Kamila Quadir, Shamim Begum* and Md Nahid Hossain  
National Institute of Nuclear Medicine & Allied Sciences, Dhaka, Society of Nuclear Medicine Bangladesh, Bangladesh

### PP104  FULLY AUTOMATED, ROBUST AND FAST ORGAN SEGMENTATION FOR VOXEL-BASED DOSE PLANNING

Mahmood Nazari1*, Masoomeh Rahimpour2, Michel Koole2, Marcus Bronzel1 and Sharok Kimiaei1  
1 Image Core Lab, BioInformat, Hybrid2020, ABX-CRO, TU-Dresden, Germany, 2 Department of Imaging & Pathology, KU Leuven, Belgium

### PP105  177Lu-SPION-CHITOSAN: NEW THERANOSTIC AND DUAL-MODALITY IMAGING PROBES IN NUCLEAR MEDICINE

Saleh Salehi Zahabi1* and Samira Rasanah2  
1 Nuclear Medicine and Radiology Department, Kermanshah University of Medical Science, Iran, 2 Medical Physics, Lorestan University of Medical Sciences, Iran

### PP106  SPECT ANGULAR SAMPLING AND SCAN TIME REDUCTION USING DEEP NEURAL NETWORKS

Seung Kwon Kang and Jae Sung Lee  
Department of Nuclear Medicine, Seoul National University, Korea

### PP107  EFFECT OF INTER-DETECTOR SCATTER RECOVERY ON PERFORMANCE OF A BRAIN-DEDICATED PET SYSTEM

Seungueun Lee1, Kyeong Yun Kim1, Min Sun Lee2 and Jae Sung Lee3  
1 Nuclear Medicine, Seoul National University, Korea, 2 Nuclear Medicine, Stanford University, USA

### PP108  VALIDATION OF RADIOIODINE SCAN BASED DOSIMETRY PROTOCOL IN DIFFERENTIATED THYROID CANCER PATIENTS

Zeenat Jabin1*, Seong Kwon2 and Henry Bom3  
1 National Institute of Nuclear Medicine & Allied Sciences (NINMAS), Bangladesh Atomic Energy Commission, Bangladesh, 2 Nuclear Medicine, Chonnam National University Hwasun Hospital (CNUHH), Korea

### PP109 - PP136 OTHERS

### PP109  DEVELOPMENT OF A NEW METHOD FOR THE MICROBIOLOGICAL ANALYSIS OF IODINE 131

Abdelmjid Aiboud1, Abdellah Ettabia, Younes Ghamad, Zine El Abidin Ayaz, Mouhsine Aitsaid, Aziz Filali and Naoual Bentaleb  
Department of Production of Radiopharmaceuticals, National Energy Center of Nuclear Science and Technology (CNESTEN) - Morocco, Morocco

### PP110  ANALYSIS NATRIUM IODIDE SYMPORTER EXPRESSION OF THYROID TUMOR PATIENTS IN PADANG CITY

Aisyah Elliyanti1*, Rony Rustam2*, Yenita Yenita2*, Tofrizal Tofrizal3* and Yayi Susanto1*  
1 Medical Physics/Radiology, Faculty of Medicine Universitas Andalas Padan, West Sumatera, Indonesia, 2 Department of Surgery Medical Faculty, Universitas Andalas Padan, Indonesia, 3 Department of Pathology Anatomy, Medical Faculty, Universitas Andalas Padang, Indonesia, 4 Department of Pathology Anatomy, Medical Faculty, Universitas Indonesia, Jakarta, Indonesia

### PP111  THERANOSTIC PARADOX: A REPORT OF TWO CASES

Azmal Sarker*, Samira Sharmin and Hosne Rahman  
Radioiodine Therapy, Institute of Nuclear Medicine and Allied Sciences (INMAS), Mitford, Dhaka, Bangladesh

### PP112  PRODUCTION OF SN-117M IN THE BR2 HIGH-FLUX REACTOR

Bernard Ponsard1*, Jaime Simon2, Zech Sandlin2 and Nigel Stevenson1  
1 BR2 Reactor, Belgian Nuclear Research Centre (SCK.CEN), Belgium, 2 IsoTherapeutics Group, LLC, USA, 3 Serene, LLC, USA
PP113 OVERVIEW OF RADIONUCLIDE PRODUCTION PROGRAM WITH RFT-30 CYCLOTRON
Chirag K. Vyas, Jun Young Lee, Min Goo Hur, Seung Dae Yang, Young Bae Kong, Eun Je Lee and Jeong Hoon Park
Cyclotron Application and Research Facility, Radiation Instrumentation Research Division, Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup Si, Jeollabuk Do, Korea

PP114 IMPACT OF COLD EXPOSURE IN BROWN ADIPOSE TISSUE IMAGING USING TSPO PET TRACER
Chiwoo Oh1, Jaeho Jung1, In Ho Song2, Byung Chul Lee3, Byung Seok Moon4, Wooseung Lee5, Miyeon Jeon5, Jinyeong Choi5 and Hyung-Jun Im1
1 Graduate School of Convergence Science and Technology, Seoul National University, Korea, 2 Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Korea

PP115 GRAPHENE OXIDE-QUENCHING-BASED FLUORESCENCE IN SITU HYBRIDIZATION (G-FISH) TO DETECT RNA IN TISSUE: SIMPLE AND FAST TISSUE RNA DIAGNOSTICS
Do Won Hwang and Yoori Choi
Nuclear Medicine, Seoul National University, Korea

PP116 COMPARABILITY OF 67CU-SARTATE AND 177LU-DOTA-OCTREOTATE EFFICACY IN A PRECLINICAL MODEL OF NEUROENDOCRINE TUMOURS
Carleen Cullinane1, Charmaine Jeffery1, Rachael Walker2, Peter Roselt1, David Binns1, Amos Hedt2, Ellen Van Dam2, Matthew Harris3, Michelle Parker4, Paul Donnelly1 and Rodney Hicks1
1 Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Australia, 2 R&D, Clarity Pharmaceuticals, Australia, 3 Translational Research Laboratory, Peter MacCallum Cancer Centre, Australia, 4 Department of Chemistry, The University of Melbourne, Australia

PP117 PROTECTIVE EFFECT OF EXTRACELLULAR VESICLES RELEASED FROM THE NEURAL STEM CELLS ON 6-HYDROXYDOPAMINE INDUCED PATHOLOGICAL BRAIN CONDITION OF PARKINSON'S DISEASE
Eun Ji Lee and Do Won Hwang
Nuclear Medicine, Seoul National University Hospital, Korea

PP118 177LU-DOTA-TOC INHIBITS CELL PROLIFERATION BY INDUCING AUTOPHAGY AND G2/M CELL ARREST IN NEUROENDOCRINE PROSTATE CANCER CELL
Fan Qiu, Wei Qu, Chuan Zhang, Yan Li and Feng Wang
Nuclear Medicine, Nanjing First Hospital Affiliated to Nanjing Medical University, China

PP119 OBSERVATION OF RNA MODIFICATION AS A NEW THERANOSTICS TARGET IN NEUROINFLAMMATION
Geonnyeong Jang1 and Yoori Choi2
1 Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Korea, 2 Department of Nuclear Medicine, Seoul National University Hospital, Korea

PP120 IN VIVO PET IMAGING OF BROWN ADIPOSE TISSUE USING TRANSLOCATOR PROTEIN 18 KDA (TSPO)-TARGETING PET: A COMPARATIVE STUDY WITH F-18 FDG
Ho Rim Oh1, Mi Jeong Kim2, Hyewon Yoon1, June-Key Chung1, Gi Jeong Cheon1, Min Seok Suh2, Jin Chunl Paeng2, Jae Ho Jung2, Sang Eun Kim1, Byung Chul Lee3 and Keon Wook Kang2
1 Department of Nuclear Medicine, Seoul National University, Korea, 2 Department of Nuclear Medicine, Seoul National University Hospital, Korea, 3 Department of Nuclear Medicine, Seoul National University Bundang Hospital, Korea

PP121 STUDY OF THERANOSTIC TARGETS VIA NEUROINFLAMMATION AND BLOOD-BRAIN BARRIER DISRUPTION IN EARLY ANIMAL MODEL OF ALZHEIMER'S DISEASE
Hoon Young Sub, Youngsun Lee and Yoori Choi
Department of Nuclear Medicine, Seoul National University Hospital, Korea
ENHANCED BREAST CANCER PROLIFERATION BY CANCER EXOSOME-STIMULATED GLIAL CELLS AND THE POTENTIAL OF CANCER-DERIVED EXOSOME AS A THERAPEUTIC TARGET
Da Yi Jeong, Jin Hye Oh and Do Won Hwang
1 Molecular Medicine and Biopharmaceutical Science, Seoul National University, Korea, 2 Molecular Medicine and Biopharmaceutical Science, Seoul National University Hospital, Korea

TECHNICAL EXPERIENCES ON THERANOSTICS IN THE PHILIPPINES: RADIOLABELING, QUALITY CONTROL AND PATIENT ADMINISTRATION SETUP
Melvin Estonactoc, Joana Marie Almazan, Michael Torres and Patricia Bautista
PET Center, Nuclear Medicine Department, St. Luke’s Medical Center, Philippines

BIOMIMETIC DESIGN FOR AVOIDING IMMUNE BARRIERS OF MACROPHAGE WITH RBC MEMBRANE CLOAKED 89ZR LABELED NANOPARTICLES
Jun Young Lee, Chirag K Vyas, Pyeong Seok Choi, Min Goo Hur, Seung Dae Yang, Young Bae Kong, Eun Je Lee, Ho Seung Song and Jeong Hoon Park
Radiation Instrumentation Research Division, Korea Atomic Energy Research Institute, Korea

COMPARATIVE ANALYSIS OF TSPO-TARGETING PET/MR AND RECRUITMENT OF PERIPHERAL IMMUNE CELLS USING BIOLUMINESCENCE IMAGING IN NEURO-INFLAMMATORY MOUSE MODEL
Kyungmin Kim, Ja Kim, Juri Na, Chul-Hee Lee, Min Sun Lee, Guen Bae Ko, Kyeong Yun Kim, Jae Ho Jung, Byung Seok Moon, Sang Eun Kim, Byungchul Lee, Jae Sung Lee, Gi Jeong Cheon, Jin Chul Paeng, June-Key Chung, Keon Wook Kang and Hyewon Youn
1 Department of Nuclear Medicine, Biomedical Sciences, Seoul National University College of Medicine, Korea, 2 Department of Nuclear Medicine, Seoul National University College of Medicine, Korea, 3 Department of Nuclear Medicine, Seoul National University Bundang Hospital, Korea, 4 Department of Nuclear Medicine, Seoul National University Hospital, Korea

TECHNICAL EXPERIENCES ON THERANOSTICS IN THE PHILIPPINES: RADIOLABELING, QUALITY CONTROL AND PATIENT ADMINISTRATION SETUP
Melvin Estonactoc, Joana Marie Almazan, Michael Torres and Patricia Bautista
PET Center, Nuclear Medicine Department, St. Luke’s Medical Center, Philippines

TECHNICAL EXPERIENCES ON THERANOSTICS IN THE PHILIPPINES: RADIOLABELING, QUALITY CONTROL AND PATIENT ADMINISTRATION SETUP
Michael Torres
Nuclear Medicine, St. Luke’s Medical Center - Quezon City, Philippines

BIODISTRIBUTION OF 177LUTETIUM-(R)-NODAGA-PSMA IN MALE WISTAR STRAIN RATS
Brigitta Silalahi, Rini Shintawati, Achmad Kartamihardja, Neneng Rosilawati and Nur Hidayati
1 Faculty of Medicine, Padjadjaran University, Indonesia, 2 Nuclear Medicine, Hasan Sadikin Hospital, Indonesia, 3 Nuclear Medicine, Faculty of Medicine Padjadjaran University / Hasan Sadikin Hospital, Indonesia, 4 Centre of Metrology and Radiation Safety Technology, Atomic Nuclear Energy Indonesia, Indonesia

MODULATION OF GLUCOSE METABOLISM BY CANCER-DERIVED EXTRACELLULAR VESICLE IN TUMOR
Seo Young Kang, Eun Ji Lee, Do Won Hwang and Dong Soo Lee
1 Department of Nuclear Medicine, Seoul National University Hospital, Korea, 2 Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea

ROLE OF TSPO LIGAND-RECEPTOR BINDING ON TSPO-VDAC INTERACTION
Seok Yong Lee, Chul Hee Lee, Keon Wook Kang and Hyewon Youn
Department of Nuclear Medicine, Seoul National University Hospital, Korea
PP131 DEVELOPMENTAL CHANGES OF BRAIN METABOLIC NETWORK IN ADHD RATS
Seunggyun Ha1, Hyekyoung Lee1, Yoori Choi1, Seonhee Lim2, Hyejin Kang3, Bung-Nyun Kim4 and Dong Soo Lee5
1 Radiation Medicine Research Institute, Seoul National University College of Medicine, Korea, 2 Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea, 3 Department of Mathematical Sciences, Seoul National University, Korea, 4 Division of Child and Adolescent Psychiatry, Department of Psychiatry, Seoul National University College of Medicine, Korea

PP132 CAVEOLIN-1 INCREASES CELL TO CELL TRANSMISSION IN PARKINSON’S DISEASE
Tae-Young Ha and Sang Myun Park
Pharmacology, Ajou Medical University, Korea

PP133 RNA-SEQ REVEALS TUMOR RADIATION RESPONSE AND NOVEL MOLECULAR TARGETS ON A-EMITTING META-[AT-211] ASTATO-BENZYLGUANIDINE THERAPY FOR MALIGNANT PHEOCHROMOCYTOMA
Tetsuya Sakashita1, Yasuhiro Ohshima1, Nobuaki Kono1, Yuichiro Yokota1, Shigeki Watanabe1, Ichiro Sasaki1, Noriko Ishioka1 and Kazuhiro Arikawa1
1 Radiation-Applied Biology Research, National Institutes for Quantum and Radiological Science and Technology, Japan, 2 Institute for Advanced Biosciences, Keio University, Japan

PP134 [225AC]AC-DOTAZOL FOR A-THERAPY OF BONE METASTASES: SYNTHESIS AND IN VIVO EVALUATION
Jean-Philippe Sinnes1, Nina Pfannkuchen1, Nicole Bausbacher2, Stefanie Pektor1, Matthias Miederer2, Marian Meckel3 and Frank Roesch1
1 Institute for Nuclear Chemistry, Johannes-Gutenberg University, Germany, 2 Department of Nuclear Medicine, University Medical Center Mainz, Germany, 3 ITG Isotope Technologies, ITG Isotope Technologies, Germany

PP135 DIAGNOSIS OF ALZHEIMER’S DISEASE THROUGH FUNCTIONAL BRAIN CONNECTIVITY REPRESENTED BY STRUCTURAL CHANGES OF BRAIN CELLS
Yoori Choi1, Hyejin Kang, Youngsun Lee and Kyu Wan Kim
Department of Nuclear Medicine, Seoul National University Hospital, Korea

PP136 THE ALTERATION OF EXPRESSION OF LONG NONCODING RNA ASSOCIATED WITH MIRNA101-A IN ALZHEIMER’S DISEASE MODEL
Youngsun Lee1 and Yoori Choi1
1 Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul National University Hospital, Seoul, Korea, 2 Department of Nuclear Medicine, Seoul National University Hospital, Korea
Modular-Lab PharmTracer

GMP compliant production

Available Tracer

<table>
<thead>
<tr>
<th>Rad</th>
<th>FLT</th>
<th>PET</th>
<th>FEC</th>
<th>F-Dopa Elect/Nuc.pl.</th>
<th>F-Miso</th>
<th>¹¹C Choline</th>
</tr>
</thead>
<tbody>
<tr>
<td>¹³C Methione</td>
<td>¹³C Acetate</td>
<td>⁹⁹mTc</td>
<td>⁹⁹Tc</td>
<td>¹⁷⁷Lu</td>
<td>⁶⁸Ga PSMA</td>
<td>⁶⁸Ga DOTA-TATE DOTA-TOC DOTA-NOC</td>
</tr>
</tbody>
</table>

System Specification

<table>
<thead>
<tr>
<th>Sterile Cassette</th>
<th>Cleaning necessary</th>
<th>GMP</th>
<th>GAMPS</th>
<th>Automated</th>
<th>Radio Chemistry support</th>
<th>International service</th>
<th>21 CFR part 11 compliant</th>
<th>ISO9001</th>
<th>Control Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>YES</td>
<td>NO</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>Laptop or Tablet</td>
</tr>
</tbody>
</table>

* E&Z offers documentation-IQ, OQ & PQ
* E&Z can support clinical trials with DMF, etc.

⁶⁸Gallium labeled components become more widely used for positron emission tomography (PET). The easy and cyclotron independent availability of ⁶⁸Gallium advances this trend. To facilitate the daily work with ⁶⁸Gallium, Eckert & Ziegler has developed an innovative and ultra smart radiosynthesis system.

Preclinical Imaging Solutions

4X4D integrated PET/SPECT/Optical/CT

- Unique Features
  - 0.15 mm SPECT & 0.6 mm PET
  - Simultaneous PET / SPECT
  - Simultaneous multi-isotope PET & SPECT
  - Sub-mm α- and β-therapy imaging
  - Positron range-free PET: e.g. 0.75 mm resolution for 124I, 82Rb, 86Y
  - Bioluminescence, Cherenkov, Fluorescence (2D, 3D, 4D)
  - Adaptive ultra-fast and ultra-high resolution X-ray CT
PRECISELY FOR ME.

Dedicated to giving cancer patients better answers than „maybe“.

www.itm.ag
- Work area with air quality conforming to Class A “At rest” (EEC-GMP) and equipped with laminar flow on the entire area
- Dose calibrator compartment set-up
- 17” monitor integration set-up
- Shielded generator compartment set-up to automatically lift 2 Mo99/Tc99m generators up
- Shielded solid waste compartment set-up
- Visual area made with sliding shielded glass on the front side

$^{68}$Ge/$^{68}$Ga GENERATOR

Easy and direct labeling of PET tracers
Global company focused on theranostic bio-pharmaceuticals

Bio-imaging business
- Bio-imaging company specialized in radioactive pharmaceuticals
- Development of radiopharmaceutical for diagnosis of prostate cancer, diagnosis of cardiovascular diseases and detection of outbreak lymph nodes
- Maximize sales through drug import and export business

Business partnerships with various institutions
- Established close relationship with SNU and Korea University Hospital, including patent transfer and clinical studies
- Secured sales when pipeline items are approved
- Joint research and product sales with global pharmaceutical companies

Projects supported by government research fund
- Korea Drug Development Fund: Development of novel radiopharmaceutical for PSMA targeted therapy
- Ministry of Trade, Industry and Energy: Development of 68Ga MSA kit for cardio & cerebrovascular imaging diagnosis
- Ministry of Trade, Industry and Energy: Development of novel radiopharmaceutical for Prostate cancer targeted imaging diagnosis

Cold vials for new radiopharmaceuticals

<table>
<thead>
<tr>
<th>Pipeline</th>
<th>Application Area</th>
<th>Development Stage</th>
<th>Cooperation Development</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Non-clinical</td>
<td>Phase I</td>
</tr>
<tr>
<td><strong>99mTc-MSA</strong></td>
<td>Prostate cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>99mTc-Iodine</strong></td>
<td>Cerebrovascular imaging diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>68Ga-NOTA-MPA</strong></td>
<td>Prostate cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>68Ga-NOTA</strong></td>
<td>Cardiovascular disease diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>68Ga-NOTA</strong></td>
<td>Image-guided surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>68Ga-NOTA</strong></td>
<td>Prostate cancer diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>68Ga-NOTA</strong></td>
<td>Prostate cancer therapy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cold vials for Tc-99m-based generic radiopharmaceuticals

<table>
<thead>
<tr>
<th>Item</th>
<th>Application</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mebrofenin</td>
<td>liver scintigraphy</td>
<td>Launched in 2018</td>
</tr>
<tr>
<td>MDP</td>
<td>bone scintigraphy</td>
<td></td>
</tr>
<tr>
<td>DMSA</td>
<td>kidney scintigraphy</td>
<td></td>
</tr>
<tr>
<td>MIBI</td>
<td>heart perfusion scintigraphy</td>
<td>To be launched in 2019</td>
</tr>
<tr>
<td>HMPAO</td>
<td>Brain scintigraphy</td>
<td></td>
</tr>
<tr>
<td>MAG-3</td>
<td>kidney scintigraphy (imported from ROTOP)</td>
<td></td>
</tr>
<tr>
<td>Tetrofosmin</td>
<td>heart perfusion scintigraphy (imported from ROTOP)</td>
<td></td>
</tr>
</tbody>
</table>
Discovery MI is the only PET/CT system today that combines the sensitivity of digital detection with the most advanced image reconstruction technology available, Time-of-Flight and Q.Clear. With the outstanding sensitivity and resolution enabled by this combination of technologies, the benefit of digital PET is clear. It enables you to continue your efforts to diagnose and stage disease earlier. This is how we’re delivering on the promise of digital PET with Discovery MI.

Discovery MI was created to help you change patient lives for the better and push the boundaries of medicine beyond its daily practice. We see it as much more than a new imaging product, it’s a PET/CT system for true discovery.
Biograph Vision
see a whole new world of precision

Expanding precision medicine.

The healthcare market operates in a constant state of flux, which can be challenging as you strive for better clinical outcomes, faster workflow, and consistent quality of results.

What if you were able to visualize smaller lesions, get information for more accurate staging and patient risk stratification, and manage operational inefficiencies to facilitate the most appropriate treatment strategy?

3.2 mm LSO crystals
Fast time of flight at 214 ps
High effective sensitivity at 100 cps/kBq
100% sensor coverage

Accuracy to reveal the bigger picture.
Performance to maximize efficiency.
Reproducibility to understand disease progression.

Learn more about Biograph Vision at siemens.com/vision

Impressive clarity and remarkable delineation are hallmarks of Biograph Vision scans. Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

1Based on internal measurements (resolution and time of flight) compared to current systems. Data on file. Biograph Vision is not commercially available in all countries. Its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.